Combination formulation comprising sacubitril-valsartan and SGLT-2 inhibitor having improved stability and dissolution rate

MYPI2025006103A0Undetermined Publication Date: 2024-10-05HANMI PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025006103
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-22
Filing Date
2024-04-04
Publication Date
2024-10-05

AI Technical Summary

Technical Problem

Current treatments for heart failure, particularly heart failure with preserved ejection fraction (HFpEF), lack effective options, and existing formulations of sacubitril-valsartan have poor stability and water solubility, limiting their therapeutic efficacy.

Method used

A combination formulation of sacubitril-valsartan and an SGLT-2 inhibitor, such as dapagliflozin, is developed to enhance stability and dissolution rate, utilizing a multilayer or drug-coated tablet design with specific excipients and disintegrants to ensure immediate release and synergistic effect.

Benefits of technology

The combination preparation achieves improved stability and bioequivalence of sacubitril-valsartan and SGLT-2 inhibitors, providing a synergistic therapeutic effect for heart failure while minimizing the generation of related substances and ensuring rapid pharmacological action.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025006103_DRAWING_001
    Figure PI2025006103_DRAWING_001
  • Figure PI2025006103_DRAWING_002
    Figure PI2025006103_DRAWING_002
  • Figure PI2025006103_DRAWING_003
    Figure PI2025006103_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical combination formulation which has a synergistic effect in the treatment of heart failure by containing both sacubitril-valsartan and an SGLT-2 inhibitor as active ingredients, and at the same time, ensures bioequivalence between the drugs because the effect of one drug on the dissolution of the other drug is minimized. In addition, the generation of impurities in the pharmaceutical combination formulation is inhibited, and thus the stability of the active ingredients is also excellent.
Need to check novelty before this filing date? Find Prior Art

Description

Combination formulation containing sacubitril-valsartan and an SGLT-2 inhibitor with improved stability and dissolution rate

[0001] The present invention relates to a combination preparation comprising sacubitril-valsartan and an SGLT-2 inhibitor as active ingredients, and having excellent stability and dissolution rate.

[0002] Heart failure is a general term for a condition in which the heart's ability to fill (diastolic) or pump (systolic) with blood is reduced due to structural or functional abnormalities in the heart, resulting in the heart's inability to properly supply the necessary blood to the body's tissues. Regardless of the cause, heart failure can lead to a decline in myocardial function, left ventricular remodeling, hemodynamic changes, neurohormonal activation, cytokine expression, and endothelial dysfunction, which can lead to various complications such as arrhythmias, atrial fibrillation, stroke, acute pulmonary edema, renal impairment, and sudden death.

[0003] As the number of patients with heart failure, particularly heart failure with preserved ejection fraction (HFpEF), increases worldwide, expectations are high for the development of related drugs due to the lack of approved treatments. The recently introduced Entresto™ (sacubitril-valsartan combination), a new heart failure treatment, is attracting attention as the first treatment to surpass existing ACE inhibitors.

[0004] The active ingredient of Entresto™ is sacubitril-valsartan sodium 2.5 hydrate, and its contents are disclosed in International Patent Publication No. WO 2007 / 056546 A1 (Patent Document 1) (the entire contents of the above patent document are hereby incorporated by reference into this specification as prior art). Although Entresto™ is effective in reducing the risk of death from cardiovascular disease and heart failure, it has been reported to have poor stability and water solubility, and very poor ease of formulation.

[0005] Meanwhile, recent large-scale clinical trials both domestically and internationally have confirmed that SGLT2 inhibitors, previously marketed as diabetes medications, are effective in treating heart failure, regardless of the presence or absence of diabetes. In the 2022 revised heart failure treatment guidelines recently released by the Korean Heart Failure Society, sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as Forxiga and Jardiance, in addition to Entresto™, were recommended as first-line standard treatments (Class I, Evidence Grade A).

[0006] Accordingly, the inventors of the present invention attempted to develop a combination formulation containing both sacubitril-valsartan and an SGLT2 inhibitor to enhance the therapeutic effect of heart failure and ischemic heart disease, and furthermore, by considering the sites of action of these drugs, developed a combination formulation form of the present invention that enables rapid release of both components while also having excellent stability, thereby completing the present invention.

[0007] (Patent Document 1) International Patent Publication No. 2007 / 056546

[0008] (Patent Document 2) U.S. Patent No. 6515117

[0009] One object of the present invention is to provide a combination preparation for oral administration that contains both sacubitril-valsartan and an SGLT-2 inhibitor as active ingredients, thereby having a synergistic effect on the treatment of heart failure, while also having a dissolution profile equivalent to that of single administration of these drugs individually, and also having excellent stability.

[0010] Another object of the present invention is to provide a method for efficiently manufacturing a composite formulation for oral administration provided by the present invention.

[0011] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.

[0012] According to one embodiment of the present invention, there is provided a pharmaceutical combination preparation comprising (1) a first release portion comprising sacubitril-valsartan, or a pharmaceutically acceptable salt thereof, as an active ingredient; and (2) a second release portion comprising a sodium-glucose cotransporter 2 (SGLT-2) inhibitor or a pharmaceutically acceptable salt thereof, as an active ingredient.

[0013] In the present invention, the first emission unit and the second emission unit may be physically separated from each other.

[0014] In the present invention, the pharmaceutical combination preparation may be a multilayer tablet or a drug-coated tablet.

[0015] In the present invention, the SGLT-2 inhibitor may be selected from the group consisting of dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, sotagliflozin, ipragliflozin, tofogliflozin, luseogliflozin, bexagliflozin, and remogloflozin.

[0016] In the present invention, the first release portion or the second release portion may include one or more pharmaceutically acceptable additives selected from the group consisting of excipients, disintegrants, and lubricants.

[0017] In the present invention, the excipient may be selected from the group consisting of microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminosilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose hydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate hydrate, calcium carbonate, sugars, and mixtures thereof.

[0018] In the present invention, the disintegrant may be selected from the group consisting of crospovidone, methylcellulose, cross-linked carboxymethylcellulose sodium (Cross-linked CMC Na, C.CMC Na, or croscarmellose sodium), carboxymethylcellulose calcium, sodium starch glycolate, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, alginic acid or its sodium salt, and combinations thereof.

[0019] In the present invention, the lubricant may be selected from the group consisting of calcium stearate, colloidal silicon dioxide (fumed silica, Aerosil), glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid, hardened vegetable oil, polyethylene glycol, sodium benzoate, talc, and combinations thereof.

[0020] In the present invention, the second emission unit may include a coating agent.

[0021] In the present invention, the coating agent may be at least one selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), polyvinyl alcohol (PVA), macrogol polyvinyl alcohol graft copolymer, polymers of acrylic acid and salts thereof, polymethacrylate, poly(butyl methacrylate, 2-dimethylaminoethyl methacrylate, methyl methacrylate) copolymer, carboxymethylcellulose, ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethyl cellulose, hydroxypropylcellulose (HPC), L-HPC (low-substituted HPC), polyvinylpyrrolidone (PVP), vinylpyrrolidone-vinylacetate copolymer, gelatin, guar gum, partially hydrolyzed starch, alginate, xanthan, and mixtures thereof.

[0022] In the present invention, the first release unit may include 10 to 80 wt% of an active ingredient, 1 to 50 wt% of an excipient, 5 to 50 wt% of a disintegrant, and 0.1 to 20 wt% of a lubricant based on the total weight.

[0023] In the present invention, the second release unit may include, based on the total weight, 0.5 to 50 wt% of an active ingredient, 20 to 95 wt% of an excipient, 0.1 to 20 wt% of a disintegrant, and 0.1 to 20 wt% of a lubricant.

[0024] In the present invention, the second release unit may include 10 to 70 wt% of the effective ingredient and 30 to 90 wt% of the coating agent based on the total weight.

[0025] In the present invention, the first release portion may include, based on the total weight of the first release portion, 10 to 80 wt% of an active ingredient, 5 to 50 wt% of at least one of microcrystalline cellulose and mannitol, 5 to 30 wt% of low-substituted hydroxypropyl cellulose, 5 to 30 wt% of at least one of sodium starch glycolate and sodium croscarmellose, 0.1 to 10 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 10 wt% of magnesium stearate.

[0026] In the present invention, the second release portion may include, based on the total weight of the second release portion, 0.5 to 50 wt% of an active ingredient, 10 to 50 wt% of at least one of microcrystalline cellulose and lactose hydrate, 10 to 50 wt% of mannitol, 0.1 to 20 wt% of hydroxypropyl cellulose, 0.5 to 20 wt% of croscarmellose sodium, and 0.5 to 20 wt% of stearyl fumarate sodium.

[0027] In the present invention, the pharmaceutical combination preparation may be a bilayer tablet comprising a first layer including a first release portion comprising the sacubitril-valsartan, or a pharmaceutically acceptable salt thereof, as an active ingredient; and a second layer including a second release portion comprising the SGLT-2 inhibitor, or a pharmaceutically acceptable salt thereof, as an active ingredient.

[0028] In the present invention, the pharmaceutical combination preparation may be a drug-coated tablet comprising a core including a first release portion comprising the sacubitril-valsartan, or a pharmaceutically acceptable salt thereof, as an active ingredient; and a coating layer including a second release portion comprising the SGLT-2 inhibitor, or a pharmaceutically acceptable salt thereof, as an active ingredient, positioned on at least a portion of the surface of the core.

[0029] In the present invention, the first release portion comprises granules containing the active ingredient of sacubitril-valsartan or a pharmaceutically acceptable salt thereof, an excipient, a disintegrant and a lubricant, and a post-mixing portion containing the disintegrant and the lubricant.

[0030] The second release portion may include granules containing the active ingredient of the SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof, an excipient, a disintegrant and a lubricant, and a post-mixing portion containing the disintegrant and the lubricant.

[0031]

[0032] According to another embodiment of the present invention, there is provided a method for preparing a pharmaceutical combination preparation, comprising the steps of: (a) preparing a first release portion comprising sacubitril-valsartan or a pharmaceutically acceptable salt thereof as an active ingredient; (b) preparing a second release portion comprising an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient; and (c) formulating the first release portion and the second release portion into one solid preparation.

[0033] In the present invention, step (a) may include a step of preparing granules comprising sacubitril-valsartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and a step of mixing the granules with a post-mixing portion comprising a disintegrant and a lubricant; step (b) may include a step of preparing granules comprising an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and a step of mixing the granules with a post-mixing portion comprising a disintegrant and a lubricant; and step (c) may include a step of compressing the mixed powder of step (a) and the mixed powder of step (b) to prepare a bilayer tablet.

[0034] In the present invention, the step (a) may include a step of preparing granules containing sacubitril-valsartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; a step of mixing the granules with a post-mixing portion containing a disintegrant and a lubricant; and a step of compressing the mixed portion to prepare a tablet, and the step (b) may include a step of preparing a coating solution by mixing an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof and a coating agent, and the step (c) may include a step of coating the coating solution of the step (b) on the surface of the tablet of the step (a) to prepare a drug-coated tablet.

[0035] The oral combination formulation provided by the present invention comprises both sacubitril-valsartan and an SGLT-2 inhibitor as active ingredients, thereby exhibiting a synergistic effect in the treatment of heart failure, while minimizing the effect of drug dissolution between the individual drugs, thereby ensuring bioequivalence. Furthermore, the oral combination formulation of the present invention suppresses the formation of related substances, thereby exhibiting excellent stability of the active ingredient.

[0036] Figure 1 is a drawing showing the results of an experiment comparing the dissolution rates of dapagliflozin under pH 1.2 conditions for the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 1.

[0037] Figure 2 is a drawing showing the results of an experiment comparing the dissolution rates of sacubitril under pH 1.2 conditions for the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 1.

[0038] Figure 3 is a drawing showing the results of an experiment comparing the dissolution rates of valsartan under pH 1.2 conditions for the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 1.

[0039] Figure 4 is a drawing showing the results of an experiment comparing the dissolution rates of dapagliflozin under pH 6.8 conditions for the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 1.

[0040] Figure 5 is a drawing showing the results of an experiment comparing the dissolution rates of sacubitril under pH 6.8 conditions for the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 1.

[0041] Figure 6 is a drawing showing the results of an experiment comparing the dissolution rates of valsartan under the conditions of a pH 6.8 solution, targeting the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 1.

[0042] Figure 7 is a drawing showing the results of an experiment comparing the amount of generated dapagliflozin RRT 0.38 flexible substances under initial, accelerated or harsh conditions for the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 2.

[0043] Figure 8 is a drawing showing the results of an experiment comparing the amount of generated dapagliflozin RRT 0.74 flexible substances under initial, accelerated or harsh conditions for the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 2.

[0044] Figure 9 is a drawing showing the results of an experiment comparing the amount of generated dapagliflozin RRT 1.59 flexible substances under initial, accelerated or harsh conditions for the combined preparations of Examples 1 to 3 and Comparative Examples 1 to 5 and the control drug in Experimental Example 2.

[0045] According to one embodiment of the present invention, there is provided a pharmaceutical combination preparation comprising (1) a first release portion comprising sacubitril-valsartan or a pharmaceutically acceptable salt thereof as an active ingredient; and (2) a second release portion comprising a sodium-glucose cotransporter 2 (SGLT-2) inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient.

[0046] In the composite formulation according to the present invention, the first release portion and the second release portion may exist in a physically separated state from each other.

[0047] In the present invention, the above-mentioned composite preparation may be in the form of a bilayer tablet or a multilayer tablet, or may be in the form of a drug-coated tablet with a core-shell structure.

[0048] In the two-layer or multi-layer tablet of the present invention, the first layer may include a first emission portion or a second emission portion, and the second layer may include a second emission portion or a first emission portion.

[0049] In the present invention, the drug-coated tablet may have a structure including a core and a coating layer coated on at least a portion of the surface of the core. In the present invention, the core may include a first release portion or a second release portion, and the coating layer may include a second release portion or a first release portion.

[0050] In one example, the first layer may comprise an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof, and the second layer may comprise sacubitril-valsartan or a pharmaceutically acceptable salt thereof.

[0051] In another example, the combination formulation may be a bilayer tablet comprising a first layer comprising sacubitril-valsartan, or a pharmaceutically acceptable salt thereof, as an active ingredient; and a second layer comprising an SGLT-2 inhibitor, such as dapagliflozin, or a pharmaceutically acceptable salt thereof, as an active ingredient.

[0052] In the drug-coated tablet of the present invention, the core may be formed as a first release portion, and the drug coating layer may be formed as a second release portion.

[0053] In one example, the core may comprise sacubitril-valsartan, or a pharmaceutically acceptable salt thereof, and the coating layer may comprise an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof.

[0054] In the present invention, the first release portion and the second release portion may additionally include pharmaceutically acceptable additives such as excipients (diluents), disintegrants, lubricants, or coating agents, depending on the form of the composite formulation.

[0055] In the present invention, the above-mentioned combination preparation is a bilayer tablet or a multilayer tablet, and the first release portion or the second release portion may include one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), disintegrants, and lubricants.

[0056] In one example, the compound preparation is a bilayer tablet or a multilayer tablet, and the first release portion may include, in addition to the active ingredient, an excipient (diluent), a disintegrant, and a lubricant, and the second release portion may also include, in addition to the active ingredient, an excipient (diluent), a disintegrant, and a lubricant.

[0057] In addition, in the present invention, the composite formulation is a drug-coated tablet, and the first release portion or the second release portion may include a coating agent.

[0058] In one example, the combination formulation is a drug-coated tablet, and the first release portion may include, in addition to the active ingredient, one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), disintegrants, and lubricants, and the second release portion may include the active ingredient and a coating agent.

[0059] In another example, the compound formulation is a drug-coated tablet, the second release portion may include, in addition to the active ingredient, one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), disintegrants, and lubricants, and the first release portion may include the active ingredient and a coating agent.

[0060] According to one embodiment of the present invention, there is provided a pharmaceutical combination preparation comprising (1) a first release portion comprising sacubitril-valsartan or a pharmaceutically acceptable salt thereof as an active ingredient; and (2) a second release portion comprising a sodium-glucose cotransporter 2 (SGLT-2) inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient.

[0061] In the present invention, the “sacubitril” is a compound of 4-{[(2S,4R)-1-(4-biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-fentanyl]amino}-4-oxobutanoic acid represented by the following chemical formula 1. Sacubitril is a neprilysin (NEP) inhibitor, and is known to be activated into sacubitrilat by deethylation of esterase, thereby decomposing atrial and brain natriuretic peptide, which is a blood pressure-lowering peptide with a blood flow-reducing effect.

[0062] [Chemical Formula 1]

[0063]

[0064] In the present invention, the “valsartan” is a compound of (S)-N-(1-carboxy-2-methyl-propyl-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine represented by the following chemical formula 2. Valsartan is an angiotensin-II receptor blocker, which not only relaxes blood vessels and lowers blood pressure by blocking the action of angiotensin-II, but is also used to treat heart failure, ischemic heart disease, etc.

[0065] [Chemical Formula 2]

[0066]

[0067] In the present invention, the term “pharmaceutically acceptable salt” refers to a salt commonly used in the relevant technical field, and includes not only salts prepared with inorganic ions, inorganic acids, or organic acids, but also hydrates or solvates of the salts. Suitable sacubitril-valsartan or pharmaceutically acceptable salts thereof for the present invention include free acids or salts of 1 to 3 inorganic ions such as sodium, calcium, potassium, and magnesium, or monohydrates to trihydrates thereof.

[0068] In the first release portion of the present invention, the sacubitril or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof may be included in a molar ratio of 1:5 to 5:1, preferably in a molar ratio of 1:1, but is not limited thereto.

[0069] “Sacubitril-valsartan”, which is included as an effective active ingredient in the pharmaceutical combination preparation of the present invention, may be included in the form of a supramolecular complex of sacubitril and valsartan, or may be included in the form of a physical mixture of the free acids or salts of each component, or may include all of a single compound formed by combining these drugs through a coprecipitate, a cocrystal, a co-amorphous compound, an ionic compound, a nonionic bond, a covalent bond, a non-covalent bond, or a hydrogen bond, etc. Here, the “supramolecular complex” is intended to describe an interaction between two pharmaceutical active agents, a cation, and any existing entity such as a solvent, especially water, by a non-covalent, intermolecular bond therebetween. The interaction results in an association of species present in the supramolecular complex, which distinguishes the complex from a physical mixture of the species.

[0070] In one example, the sacubitril-valsartan may be provided in the form of a compound represented by the following chemical formula 3, but is not limited thereto.

[0071] [Chemical Formula 3]

[0072]

[0073] In the above chemical formula 3,

[0074] A1 is valsartan in anionic form;

[0075] A2 is the anionic form of sacubitril;

[0076] Na + is a sodium ion;

[0077] x may be a rational number from 0.5 to 7, preferably a rational number from 2.5 to 3.5, more preferably 2.5 or 3, but is not limited thereto.

[0078] In another example, the sacubitril-valsartan may be, but is not limited to, a supramolecular complex of sacubitril-valsartan trisodium salt trihydrate.

[0079] In another example, the sacubitril-valsartan may be, but is not limited to, sacubitril-valsartan trisodium salt trihydrate in crystalline form II represented by the following chemical formula 4:

[0080] [Chemical Formula 4]

[0081]

[0082] In another example, the sacubitril-valsartan may be, but is not limited to, a supramolecular complex of sacubitril-valsartan trisodium hemipentahydrate, conventionally referred to as 'LCZ696' (see Korean Patent No. 10-1589317).

[0083] In the present invention, the sacubitril or N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester or a pharmaceutically acceptable salt thereof as well as (2R,4S)-5-biphenyl-4-yl-4(3-carboxy-propionyl amino)-2-methyl-pentanoic acid can be prepared by known methods such as the method described in U.S. Patent No. 5,217,996, which is incorporated herein by reference.

[0084] In the present invention, the valsartan or (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-methyl}-valine) or a pharmaceutically acceptable salt thereof can be purchased from commercial sources or prepared according to known methods, such as those described in U.S. Patent No. 5,399,578 and European Patent No. 0443983, the preparation teachings of which are incorporated herein by reference. Valsartan may be used in certain embodiments of the present invention in its free acid form as well as in any suitable salt form. Depending on the circumstances, salts and derivatives of the tetrazole group as well as esters or other derivatives of the carboxyl group may be used.

[0085] In the present invention, the initial dose of sacubitril-valsartan is 50 mg twice a day (24.3 / 25.7 mg as sacubitril-valsartan), and if necessary, the dose may be increased to 200 mg twice a day (97.2 / 102.8 mg as sacubitril-valsartan).

[0086] In the pharmaceutical combination preparation of the present invention, the second release portion comprises an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof.

[0087] In the present invention, the SGLT-2 inhibitor is a benzene derivative compound substituted with glucopyranosyl, which has the ability to inhibit the sodium glucose cotransporter. In the present invention, the SGLT-2 inhibitor may be selected from the group consisting of dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, sotagliflozin, ipragliflozin, tofogliflozin, luseogliflozin, bexagliflozin, and remogloflozin, but is not limited thereto.

[0088] In one example, the SGLT-2 inhibitor may be, but is not limited to, dapagliflozin.

[0089] In another example, the SGLT-2 inhibitor may be, but is not limited to, empagliflozin.

[0090] In another example, the SGLT-2 inhibitor may be, but is not limited to, canagliflozin.

[0091] In another example, the SGLT-2 inhibitor may be, but is not limited to, ertugliflozin.

[0092] In another example, the SGLT-2 inhibitor may be, but is not limited to, sotagliflozin.

[0093] In another example, the SGLT-2 inhibitor may be, but is not limited to, ipragliflozin.

[0094] In another example, the SGLT-2 inhibitor may be, but is not limited to, tofogliflozin.

[0095] In another example, the SGLT-2 inhibitor may be, but is not limited to, luseogliflozin.

[0096] In another example, the SGLT-2 inhibitor may be, but is not limited to, bexagliflozin.

[0097] In another example, the SGLT-2 inhibitor may be, but is not limited to, remogliflozin.

[0098] In the present invention, the SGLT-2 inhibitor can be prepared according to a method known in the art, for example, as shown in International Patent Publication No. 2006 / 120208, International Patent Publication No. 2007 / 031548, or International Patent Publication No. 2008 / 002824.

[0099] In the present invention, the dapagliflozin is (1S)-1,5-anhydro-1-C-4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl-D-glucitol represented by the following chemical formula 5. Dapagliflozin inhibits SGLT-2 in the renal tubules, thereby inhibiting the reabsorption process of glucose and causing glucose to be excreted in the urine, thereby suppressing an increase in blood sugar levels.

[0100] [Chemical Formula 5]

[0101]

[0102] In the present invention, the SGLT-2 inhibitor, such as dapagliflozin, may include all forms of its pharmaceutically acceptable salt, ester, or solvate.

[0103] In the present invention, the dapagliflozin or a pharmaceutically acceptable salt thereof may be in a continuous and / or discontinuous amorphous form or in the form of a cocrystal.

[0104] In the present invention, the dapagliflozin may comprise a prodrug ester thereof. Here, the pharmaceutically acceptable ester can be cleaved in a human or animal body to produce the parent acid (e.g., when the ester is methoxymethyl) or a hydroxyl group (e.g., when the ester is acetyl ester).

[0105] In the present invention, the solvate of dapagliflozin may include or consist of a propylene glycol solvate of dapagliflozin, such as dapagliflozin propylene glycol (1:1), and in one example, the solvate of dapagliflozin may be in the form of a propylene glycol solvate hydrate (1:1:1) thereof. Here, the propylene glycol may be in the (S) form, the (R) form, or a mixture thereof, and preferably, may be in the (S) form, but is not limited thereto.

[0106] In addition, in the present invention, the solvate of dapagliflozin may be in the form of a solvate comprising dapagliflozin and a 1,2-alkanediol or a hydrate thereof. Here, the 1,2-alkanediol may be 1,2-propanediol, 1,2-butanediol, 1,2-pentanediol, 1,2-hexanediol, and 1,2-heptanediol or a hydrate or mixture thereof. In one example, the solvate of dapagliflozin may be dapagliflozin propanediol monohydrate, or may be dapagliflozin combined with (2S)-1,2-propanediol, hydrate, at a ratio of about 1:1:1, but is not limited thereto.

[0107] The second release unit of the present invention may include one or more amino acids together with the dapagliflozin. The amino acids include: glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, serine, cysteine, threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, histidine, and lysine. In addition, the dapagliflozin and the amino acid in the present invention may be in the form of a co-crystal. In one example, the second release unit may include, but is not limited to, dapagliflozin and proline (e.g., L-proline or D-proline).

[0108] The combination preparation of the present invention may contain 50 to 200 mg of the sacubitril-valsartan free base and 5 to 10 mg of dapagliflozin free base per unit dosage form. For example, the combination preparation may contain 100 mg or 200 mg of sacubitril-valsartan free base and 10 mg of dapagliflozin per unit dosage form.

[0109] Any reference in this specification to sacubitril, valsartan, SGLT-2 inhibitor or dapagliflozin should be understood to include all salts, solvates and isomers of each of the above mentioned.

[0110] In the composite formulation according to the present invention, the first release portion and the second release portion may exist in a physically separated state from each other.

[0111] In the present invention, the above-mentioned composite preparation may be in the form of a bilayer tablet or a multilayer tablet, or may be in the form of a drug-coated tablet with a core-shell structure.

[0112] In the two-layer or multi-layer tablet of the present invention, the first layer may include a first emission portion or a second emission portion, and the second layer may include a second emission portion or a first emission portion.

[0113] In the present invention, in the two-layer or multi-layer tablet, the first layer may be formed as a first emission portion, and the second layer may be formed as a second emission portion.

[0114] In one example, the first layer may comprise sacubitril-valsartan or a pharmaceutically acceptable salt thereof, and the second layer may comprise an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof.

[0115] In another example, the first layer may comprise an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof, and the second layer may comprise sacubitril-valsartan or a pharmaceutically acceptable salt thereof.

[0116] In another example, the combination formulation may be a bilayer tablet comprising a first layer comprising sacubitril-valsartan, or a pharmaceutically acceptable salt thereof, as an active ingredient; and a second layer comprising an SGLT-2 inhibitor, such as dapagliflozin, or a pharmaceutically acceptable salt thereof, as an active ingredient. Here, the descriptions of the first layer and the second layer refer to different layers (i.e., the first layer refers to any one layer of the bilayer tablet, and the second layer refers to a layer other than the layer mentioned above), and the first layer may be positioned on the upper side but may also be positioned on the lower side, or the second layer may be positioned on the lower side but may also be positioned on the upper side. In such a bilayer tablet, sacubitril and valsartan, and the SGLT-2 inhibitor are respectively included in different layers.

[0117] In the present invention, the drug-coated tablet may have a structure including a core and a coating layer coated on at least a portion of the surface of the core. In the present invention, the core may include a first release portion or a second release portion, and the coating layer may include a second release portion or a first release portion.

[0118] In the drug-coated tablet of the present invention, the core may be formed as a first release portion, and the drug coating layer may be formed as a second release portion.

[0119] In one example, the core may comprise sacubitril-valsartan, or a pharmaceutically acceptable salt thereof, and the coating layer may comprise an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof.

[0120] In another example, the core may comprise an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof, and the coating layer may comprise sacubitril-valsartan, or a pharmaceutically acceptable salt thereof.

[0121] In another example, the combination formulation may be a drug-coated tablet comprising a core comprising sacubitril-valsartan, or a pharmaceutically acceptable salt thereof, as an active ingredient; and a coating layer comprising an SGLT-2 inhibitor, such as dapagliflozin, or a pharmaceutically acceptable salt thereof, as an active ingredient.

[0122] In the present invention, the first release portion and the second release portion may additionally include pharmaceutically acceptable additives such as excipients (diluents), disintegrants, lubricants, or coating agents, depending on the form of the composite formulation.

[0123] In the present invention, the above-mentioned combination preparation is a bilayer tablet or a multilayer tablet, and the first release portion or the second release portion may include one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), disintegrants, and lubricants.

[0124] In addition, in the present invention, the composite formulation is a drug-coated tablet, and the first release portion or the second release portion may include a coating agent.

[0125] In one example, the first release portion may include, in addition to the active ingredient, one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), disintegrants, and lubricants, and the second release portion may include the active ingredient and a coating agent.

[0126] In another example, the second release portion may include, in addition to the active ingredient, one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), disintegrants, and lubricants, and the first release portion may include the active ingredient and a coating agent.

[0127] In the present invention, sacubitril-valsartan included as an active ingredient in the first release portion may be included in an amount of 10 to 80 wt%, 20 to 80 wt%, or 30 to 80 wt% based on the total weight of the first release portion, but is not limited thereto.

[0128] In the present invention, the SGLT-2 inhibitor, preferably dapagliflozin, included as an active ingredient in the second layer may be included in an amount of 0.5 to 50 wt%, 0.5 to 30 wt%, or 0.5 to 10 wt% based on the total weight of the second layer, but is not limited thereto.

[0129] In the present invention, the excipient included in the first release portion may be included in an amount of 1 to 50 wt%, 5 to 50 wt%, 5 to 30 wt%, 10 to 30 wt%, 5 to 20 wt%, 10 to 20 wt%, or 5 to 15 wt% based on the total weight of the first release portion, but is not limited thereto.

[0130] In the present invention, the excipient may be included in an amount of 20 to 95 wt%, 30 to 90 wt%, 40 to 90 wt%, 50 to 80 wt%, or 60 to 80 wt% based on the total weight of the second release portion, but is not limited thereto.

[0131] In the present invention, the disintegrant may be included in an amount of 5 to 50 wt%, 10 to 50 wt%, 10 to 40 wt%, or 15 to 30 wt% based on the total weight of the first release portion, but is not limited thereto.

[0132] In the present invention, the disintegrant may be included in an amount of 0.1 to 40 wt%, 0.1 to 20 wt%, 0.5 to 40 wt%, 0.5 to 20 wt%, 1 to 40 wt%, 5 to 40 wt%, 5 to 30 wt%, 10 to 30 wt%, 1 to 10 wt% or 1 to 5 wt% based on the total weight of the second discharge portion, but is not limited thereto.

[0133] In the present invention, the lubricant may be included in an amount of 0.1 to 20 wt%, 0.5 to 20 wt%, 1 to 10 wt%, or 2 to 8 wt% based on the total weight of the first release portion, but is not limited thereto.

[0134] In the present invention, the lubricant may be included in an amount of 0.1 to 20 wt%, 0.5 to 20 wt%, 1 to 15 wt%, 5 to 15 wt%, 1 to 10 wt%, 5 to 10 wt%, 2 to 8 wt%, or 5 to 8 wt% based on the total weight of the second release portion, but is not limited thereto.

[0135] In the present invention, the coating agent may be included in an amount of 30 to 90 wt%, 40 to 90 wt%, 40 to 80 wt%, or 50 to 80 wt% based on the total weight of the first emission portion or the second emission portion, but is not limited thereto.

[0136] In one example, the first release portion may include, but is not limited to, 10 to 80 wt% of an active ingredient, 1 to 50 wt% of an excipient, 5 to 50 wt% of a disintegrant, and 0.1 to 20 wt% of a lubricant, based on the total weight.

[0137] In one example, the second release portion may include, but is not limited to, 0.5 to 50 wt% of the active ingredient, 20 to 95 wt% of the excipient, 0.1 to 20 wt% of the disintegrant, and 0.1 to 20 wt% of the lubricant, based on the total weight.

[0138] In one example, the first or second release unit may include, but is not limited to, 10 to 70 wt% of the active ingredient and 30 to 90 wt% of the coating agent based on the total weight.

[0139] In the present invention, the excipient (diluent) may be selected from the group consisting of, but is not limited to, microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminometasilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose monohydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate monohydrate, calcium carbonate, sugars, and any mixture thereof. However, in the present invention, anhydrous calcium phosphate is not included as an excipient because it has poor compatibility with dapagliflozin and sacubitril-valsartan.

[0140] In the present invention, the disintegrant may be selected from the group consisting of, for example, crospovidone, methylcellulose, cross-linked carboxymethylcellulose sodium (Cross-linked CMC Na, C.CMC Na, or croscarmellose sodium), carboxymethylcellulose calcium, sodium starch glycolate, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, alginic acid or its sodium salt, and any combination thereof, but is not limited thereto.

[0141] In the present invention, the lubricant may be selected from the group consisting of, but is not limited to, calcium stearate, colloidal silicon dioxide (fumed silica, Aerosil), glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid, hardened vegetable oil, polyethylene glycol, sodium benzoate, talc, and any combination thereof.

[0142] In the present invention, the coating agent is a hydrophilic polymer, for example, hydroxypropylmethyl cellulose (HPMC), polyvinyl alcohol (PVA), macrogol polyvinyl alcohol graft copolymer, polymers of acrylic acid and its salts, polymethacrylate, poly(butyl methacrylate, 2-dimethylaminoethyl methacrylate, methyl methacrylate) copolymers (e.g., Eudragit® E, Evonik), carboxymethylcellulose (sodium salt and calcium salt), ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethyl cellulose, hydroxypropylcellulose (HPC), L-HPC (low-substituted HPC), polyvinylpyrrolidone (povidone; PVP), vinylpyrrolidone-vinylacetate copolymers (e.g., Kollidon® VA64, The coating material may be at least one selected from the group consisting of BASF, gelatin, guar gum, partially hydrolyzed starch, alginate, xanthan, and mixtures thereof, but is not limited thereto. Preferably, the coating material may be hydroxypropylmethylcellulose (HPMC), polyvinyl alcohol (PVA), macrogol polyvinyl alcohol graft copolymer, poly(butyl methacrylate, 2-dimethylaminoethyl methacrylate, methyl methacrylate) copolymer (e.g., Eudragit® E, Evonik).

[0143] In the present invention, the first release unit may include an additive selected from microcrystalline cellulose, mannitol, low-substituted hydroxypropyl cellulose (L-HPC), croscarmellose sodium, sodium starch glycolate, colloidal silicon dioxide (fumed silica, Aerosil), talc, magnesium stearate, and any combination thereof.

[0144] In one example, the first release unit may include additives including at least one of microcrystalline cellulose and mannitol; low-substituted hydroxypropyl cellulose (L-HPC); at least one of croscarmellose sodium and sodium starch glycolate; colloidal silicon dioxide (fumed silica, Aerosil); talc; and magnesium stearate.

[0145] In another example, the first release unit may include additives including microcrystalline cellulose, mannitol, low-substituted hydroxypropyl cellulose (L-HPC), croscarmellose sodium, fumed silica (Aerosil), talc, and magnesium stearate.

[0146] In another example, the first release unit may include additives including microcrystalline cellulose, low-substituted hydroxypropyl cellulose (L-HPC), sodium starch glycolate, fumed silica (Aerosil), talc, and magnesium stearate.

[0147] In the present invention, the first release unit may include at least one of microcrystalline cellulose and mannitol in an amount of 1 to 50 wt%, 5 to 50 wt%, 1 to 30 wt%, 5 to 30 wt%, 1 to 20 wt%, or 5 to 20 wt%, based on the total weight of the first release unit. In one example, the first release unit may include microcrystalline cellulose. In another example, the first release unit may include mannitol. In yet another example, the first release unit may include both microcrystalline cellulose and mannitol. In yet another example, the first release unit may include microcrystalline cellulose in an amount of 1 to 30 wt%, 1 to 20 wt%, or 1 to 10 wt%, but is not limited thereto. In another example, the first release unit may comprise, but is not limited to, 1 to 30 wt%, 1 to 20 wt%, or 1 to 10 wt% mannitol.

[0148] In the present invention, the first release portion may contain low-substituted hydroxypropyl cellulose in an amount of 5 to 30 wt%, 5 to 20 wt%, 5 to 15 wt%, or 10 to 20 wt% based on the total weight of the first release portion.

[0149] In the present invention, the first release unit may include at least one of sodium starch glycolate and sodium croscarmellose in an amount of 1 to 30 wt%, 5 to 30 wt%, 5 to 20 wt%, or 5 to 15 wt%, based on the total weight of the first release unit. In one example, the first release unit may include sodium starch glycolate. In another example, the first release unit may include sodium croscarmellose. In yet another example, the first release unit may include both sodium starch glycolate and sodium croscarmellose. In yet another example, the first release unit may include, but is not limited to, 1 to 30 wt%, 5 to 30 wt%, 5 to 20 wt%, or 5 to 15 wt% of sodium starch glycolate. In another example, the first release agent may comprise, but is not limited to, 1 to 30 wt%, 5 to 30 wt%, 5 to 20 wt%, or 5 to 15 wt% of croscarmellose sodium.

[0150] In the present invention, the first emission portion may contain colloidal silicon dioxide in an amount of 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, or 0.1 to 2 wt% based on the total weight of the first emission portion.

[0151] In the present invention, the first emission portion may contain talc in an amount of 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, or 0.1 to 2 wt% based on the total weight of the first emission portion.

[0152] In the present invention, the first release portion may contain magnesium stearate in an amount of 0.1 to 10 wt%, 0.1 to 5 wt%, 1 to 5 wt%, or 1 to 3 wt% based on the total weight of the first release portion.

[0153] In one example, the first release portion may include, but is not limited to, 10 to 80 wt% of the active ingredient, 5 to 50 wt% of at least one of microcrystalline cellulose and mannitol, 5 to 30 wt% of low-substituted hydroxypropyl cellulose, 5 to 30 wt% of at least one of sodium starch glycolate and sodium croscarmellose, 0.1 to 10 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 10 wt% of magnesium stearate, based on the total weight of the first release portion.

[0154] In another example, the first release portion may include, but is not limited to, 10 to 80 wt% of the active ingredient, 5 to 50 wt% of microcrystalline cellulose, 5 to 30 wt% of low-substituted hydroxypropyl cellulose, 5 to 30 wt% of sodium starch glycolate, 0.1 to 10 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 10 wt% of magnesium stearate, based on the total weight of the first release portion.

[0155] In another example, the first release portion may include, but is not limited to, 10 to 80 wt% of the active ingredient, 1 to 30 wt% of microcrystalline cellulose, 1 to 20 wt% of mannitol, 5 to 30 wt% of low-substituted hydroxypropyl cellulose, 5 to 30 wt% of croscarmellose sodium, 0.1 to 10 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 10 wt% of magnesium stearate, based on the total weight of the first release portion.

[0156] In another example, the first release portion may include, but is not limited to, 10 to 80 wt% of the active ingredient, 1 to 10 wt% of microcrystalline cellulose, 1 to 10 wt% of mannitol, 5 to 20 wt% of low-substituted hydroxypropyl cellulose, 5 to 20 wt% of croscarmellose sodium, 0.1 to 10 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 10 wt% of magnesium stearate, based on the total weight of the first release portion.

[0157] In the present invention, the second release unit may include an additive selected from microcrystalline cellulose, lactose hydrate, mannitol, hydroxypropyl cellulose, sodium stearyl fumarate, sodium croscarmellose, and any combination thereof.

[0158] In one example, the second release unit may include an additive comprising at least one of microcrystalline cellulose and lactose hydrate; mannitol; hydroxypropyl cellulose; sodium stearyl fumarate; and sodium croscarmellose.

[0159] In another example, the second release unit may include additives including microcrystalline cellulose, mannitol, hydroxypropyl cellulose, sodium stearyl fumarate, and sodium croscarmellose.

[0160] In another example, the second release unit may include additives including lactose monohydrate, mannitol, hydroxypropylcellulose, sodium stearyl fumarate, and sodium croscarmellose.

[0161] In the present invention, the second release unit may include at least one of microcrystalline cellulose and lactose hydrate in an amount of 10 to 50 wt%, 20 to 50 wt%, 10 to 40 wt%, 15 to 40 wt%, 10 to 30 wt%, or 15 to 30 wt%, based on the total weight of the second release unit. In one example, the second release unit may include microcrystalline cellulose. In another example, the second release unit may include lactose hydrate. In yet another example, the second release unit may include both microcrystalline cellulose and lactose hydrate. In yet another example, the second release unit may include microcrystalline cellulose in an amount of 10 to 50 wt%, 10 to 40 wt%, or 15 to 30 wt%. In another example, the second release unit may comprise, but is not limited to, lactose hydrate in an amount of 10 to 50 wt%, 20 to 50 wt%, 10 to 40 wt%, or 15 to 40 wt%.

[0162] In the present invention, the second release unit may contain mannitol in an amount of 10 to 70 wt%, 20 to 70 wt%, 30 to 70 wt%, 40 to 70 wt%, 10 to 60 wt%, 20 to 60 wt%, 30 to 60 wt%, 40 to 60 wt%, 10 to 50 wt%, 20 to 50 wt%, or 30 to 50 wt%, based on the total weight of the second release unit.

[0163] In the present invention, the second release portion may contain hydroxypropyl cellulose in an amount of 0.1 to 20 wt%, 0.5 to 20 wt%, 0.1 to 10 wt%, 0.5 to 10 wt%, 1 to 10 wt%, or 2 to 8 wt% based on the total weight of the second release portion.

[0164] In the present invention, the second release portion may contain croscarmellose sodium in an amount of 0.5 to 20 wt%, 1 to 20 wt%, 5 to 20 wt%, or 5 to 15 wt% based on the total weight of the second release portion.

[0165] In the present invention, the second release portion may contain sodium stearyl fumarate in an amount of 0.5 to 20 wt%, 1 to 20 wt%, 5 to 20 wt%, or 5 to 15 wt% based on the total weight of the second release portion.

[0166] In one example, the second release portion may include, but is not limited to, 0.5 to 50 wt% of an active ingredient, 10 to 50 wt% of at least one of microcrystalline cellulose and lactose hydrate, 10 to 50 wt% of mannitol, 0.1 to 20 wt% of hydroxypropyl cellulose, 0.5 to 20 wt% of croscarmellose sodium, and 0.5 to 20 wt% of stearyl fumarate sodium, based on the total weight of the second release portion.

[0167] In another example, the second release portion may include, but is not limited to, 0.5 to 50 wt% of the active ingredient, 10 to 50 wt% of microcrystalline cellulose, 10 to 50 wt% of mannitol, 0.1 to 20 wt% of hydroxypropyl cellulose, 0.5 to 20 wt% of croscarmellose sodium, and 0.5 to 20 wt% of stearyl fumarate sodium, based on the total weight of the second release portion.

[0168] In another example, the second release portion may include, but is not limited to, 0.5 to 50 wt% of the active ingredient, 10 to 30 wt% of microcrystalline cellulose, 20 to 70 wt% of mannitol, 0.5 to 20 wt% of hydroxypropyl cellulose, 0.5 to 20 wt% of croscarmellose sodium, and 0.1 to 20 wt% of sodium stearyl fumarate, based on the total weight of the second release portion.

[0169] In another example, the second release portion may include, but is not limited to, 0.5 to 50 wt% of the active ingredient, 10 to 50 wt% of lactose hydrate, 10 to 50 wt% of mannitol, 0.1 to 20 wt% of hydroxypropyl cellulose, 0.5 to 20 wt% of croscarmellose sodium, and 0.5 to 20 wt% of stearyl fumarate sodium, based on the total weight of the second release portion.

[0170] In addition, in the present invention, the first release unit may include, in addition to the effective ingredient, polyvinylpyrrolidone (povidone; PVP) and a macrogol-polyvinyl alcohol copolymer.

[0171] In the present invention, the first release portion may contain polyvinylpyrrolidone (povidone; PVP) in an amount of 1 to 20 wt%, 5 to 20 wt%, 5 to 15 wt%, or 5 to 10 wt% based on the total weight of the first release portion.

[0172] In the present invention, the first release portion may contain the macrogol-polyvinyl alcohol copolymer in an amount of 30 to 80 wt%, 40 to 80 wt%, 30 to 70 wt%, or 40 to 70 wt% based on the total weight of the first release portion.

[0173] In one example, the first release portion may include, but is not limited to, 10 to 70 wt% of the active ingredient, 5 to 20 wt% of povidone (PVP), and 30 to 80 wt% of a macrogol-polyvinyl alcohol copolymer, based on the total weight of the first release portion.

[0174] In the present invention, the second release unit may include, in addition to the effective ingredient, polyvinylpyrrolidone (povidone; PVP) and a macrogol-polyvinyl alcohol copolymer.

[0175] In the present invention, the second release unit may contain polyvinylpyrrolidone (povidone; PVP) in an amount of 1 to 20 wt%, 5 to 20 wt%, 5 to 15 wt%, or 5 to 10 wt% based on the total weight of the second release unit.

[0176] In the present invention, the second emission portion may contain the macrogol-polyvinyl alcohol copolymer in an amount of 30 to 80 wt%, 40 to 80 wt%, 30 to 70 wt%, or 40 to 70 wt% based on the total weight of the second emission portion.

[0177] In one example, the second release portion may include, but is not limited to, 10 to 70 wt% of the active ingredient, 5 to 20 wt% of povidone (PVP), and 30 to 80 wt% of a macrogol-polyvinyl alcohol copolymer, based on the total weight of the second release portion.

[0178] In the present invention, when the above-described combination preparation is manufactured in the form of a drug-coated tablet, the coating layer may additionally include various biologically inactive ingredients for additional purposes such as coating efficiency, drug stability, appearance, color, protection, maintenance, binding, performance improvement, and manufacturing process improvement. The biologically inactive ingredients that may be additionally included in the coating layer may be at least one selected from the group consisting of plasticizers, lubricants, colorants, flavoring agents, surfactants, stabilizers, antioxidants, foaming agents, anti-foaming agents, paraffin, and wax, but are not limited thereto.

[0179] In addition, in the present invention, various additives may be additionally mixed into the first release portion and / or the second release portion to improve the physical properties, manufacturability, compressibility, appearance, preference, and / or drug stability of the final obtained composite formulation. Such additives include, but are not limited to, stabilizers, solubilizers, sweeteners, flavoring agents, pigments, humectants, fillers, stabilizers, surfactants, lubricants, solubilizers, buffers, sweeteners, adsorbents, flavoring agents, binders, suspending agents, curing agents, antioxidants, brighteners, flavoring agents, flavoring agents, pigments, coating agents, humectants, moisture regulators, antifoaming agents, refreshing agents, chewing agents, antistatic agents, coloring agents, sugar coating agents, isotonic agents, softeners, emulsifiers, adhesives, thickeners, foaming agents, pH regulators, excipients, dispersants, disintegrants, waterproofing agents, preservatives, preservatives, solubilizing agents, solvents, and fluidizing agents, as long as they are pharmaceutically acceptable.

[0180] In the present invention, in the composite preparation in the form of a two-layer tablet as described above, each of the tablet-shaped layers including the first release portion and the second release portion may include granules containing an active ingredient and a post-mixing portion.

[0181] In the present invention, the layer (first layer) including the first release unit may include granules containing an active ingredient and a post-mixing unit. At this time, the granules may additionally include pharmaceutically acceptable additives such as excipients, disintegrants, or lubricants. In addition, the post-mixing unit may additionally include at least one pharmaceutically acceptable additive among disintegrants and lubricants.

[0182] In one example, the layer including the first release portion may include, but is not limited to, granules including an active ingredient, an excipient, a disintegrant, and a lubricant, and a post-mixing portion including the disintegrant and the lubricant.

[0183] In the present invention, the granules in the layer including the first release portion may contain the active ingredient in an amount of 10 to 80 wt%, 20 to 80 wt%, or 30 to 80 wt% based on the total weight of the first release portion.

[0184] In the present invention, the granules in the layer including the first release portion may contain excipients in an amount of 5 to 50 wt%, 5 to 30 wt%, or 5 to 20 wt% based on the total weight of the first release portion.

[0185] In the present invention, the granules in the layer including the first release portion may contain a disintegrant in an amount of 1 to 30 wt%, 10 to 30 wt%, or 10 to 20 wt% based on the total weight of the first release portion.

[0186] In the present invention, the granules in the layer including the first release portion may contain the lubricant in an amount of 0.1 to 10 wt%, 1 to 10 wt%, or 1 to 5 wt% based on the total weight of the first release portion.

[0187] In the present invention, the post-mixing portion within the layer including the first discharge portion may include a disintegrant in an amount of 1 to 20 wt%, 1 to 10 wt%, or 2 to 8 wt% based on the total weight of the first discharge portion.

[0188] In the present invention, the post-mixing portion within the layer including the first emission portion may include a lubricant in an amount of 0.1 to 10 wt%, 0.1 to 5 wt%, or 1 to 5 wt% based on the total weight of the first emission portion.

[0189] In one example, the granules within the layer including the first release portion may include 10 to 80 wt% of the active ingredient, 5 to 50 wt% of the excipient, 1 to 30 wt% of the disintegrant, and 0.1 to 10 wt% of the lubricant, based on the total weight of the first release portion, and the post-mixing portion may include, but is not limited to, 1 to 20 wt% of the disintegrant, and 0.1 to 10 wt% of the lubricant, based on the total weight of the first release portion.

[0190] In another example, the granules within the layer including the first release portion may include 10 to 80 wt% of the active ingredient, 5 to 50 wt% of the excipient, 1 to 30 wt% of the disintegrant, and 0.1 to 10 wt% of the lubricant based on the total weight of the first release portion, and the post-mixing portion may include, but is not limited to, 1 to 20 wt% of the disintegrant and 0.1 to 10 wt% of the lubricant based on the total weight of the first release portion.

[0191] In another example, the granules within the layer including the first release portion may include 10 to 80 wt% of the active ingredient, 5 to 20 wt% of the excipient, 10 to 30 wt% of the disintegrant, and 0.1 to 10 wt% of the lubricant based on the total weight of the first release portion, and the post-mixing portion may include, but is not limited to, 1 to 20 wt% of the disintegrant and 0.1 to 10 wt% of the lubricant based on the total weight of the first release portion.

[0192] In the present invention, the granules within the layer including the first release portion may contain at least one of microcrystalline cellulose and mannitol in an amount of 1 to 50 wt%, 5 to 50 wt%, 1 to 30 wt%, 5 to 30 wt%, 1 to 20 wt%, or 5 to 20 wt%. In one example, the granules within the layer including the first release portion may contain microcrystalline cellulose. In another example, the granules within the layer may contain mannitol. In yet another example, the granules within the layer may contain both microcrystalline cellulose and mannitol. In yet another example, the granules within the layer may contain microcrystalline cellulose in an amount of, but not limited to, 1 to 30 wt%, 1 to 20 wt%, or 1 to 10 wt%. In another example, the granules within the layer may comprise, but are not limited to, 1 to 30 wt%, 1 to 20 wt%, or 1 to 10 wt% mannitol.

[0193] In the present invention, the granules in the layer including the first emission portion may contain low-substituted hydroxypropyl cellulose in an amount of 5 to 30 wt%, 5 to 20 wt%, 5 to 15 wt%, or 10 to 20 wt%.

[0194] In the present invention, the granules within the layer including the first release portion may contain at least one of sodium starch glycolate and sodium croscarmellose in an amount of 1 to 15 wt%, 1 to 10 wt%, or 2 to 8 wt%. In one example, the granules within the layer including the first release portion may contain sodium starch glycolate. In another example, the granules within the layer may contain sodium croscarmellose. In yet another example, the granules within the layer may contain both sodium starch glycolate and sodium croscarmellose. In yet another example, the granules within the layer may contain, but are not limited to, 1 to 15 wt%, 1 to 10 wt%, or 2 to 8 wt% of sodium starch glycolate. In yet another example, the granules within the layer may contain, but are not limited to, 1 to 15 wt%, 1 to 10 wt%, or 2 to 8 wt% of sodium croscarmellose.

[0195] In the present invention, the granules in the layer including the first emission portion may contain colloidal silicon dioxide in an amount of 0.1 to 5 wt%, 0.1 to 3 wt%, or 0.1 to 2 wt%.

[0196] In the present invention, the granules in the layer including the first emission portion may contain talc in an amount of 0.1 to 10 wt%, 0.1 to 5 wt%, or 1 to 5 wt%.

[0197] In the present invention, the granules in the layer including the first release portion may contain magnesium stearate in an amount of 0.1 to 5 wt%, 0.5 to 5 wt%, or 1 to 5 wt%.

[0198] In one example, the granules in the layer including the first release portion may include, based on the total weight of the first release portion, 10 to 80 wt% of the active ingredient, 1 to 50 wt% of at least one of microcrystalline cellulose and mannitol, 5 to 30 wt% of low-substituted hydroxypropyl cellulose, 1 to 15 wt% of at least one of sodium starch glycolate and sodium croscarmellose, 0.1 to 5 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 5 wt% of magnesium stearate, and the post-mixing portion may include, but is not limited to, 1 to 15 wt% of sodium starch glycolate, 0.1 to 5 wt% of colloidal silicon dioxide, and 0.1 to 5 wt% of magnesium stearate, based on the total weight of the first release portion.

[0199] In another example, the granules in the layer including the first release portion may include, based on the total weight of the first release portion, 10 to 80 wt% of the active ingredient, 5 to 50 wt% of microcrystalline cellulose, 5 to 30 wt% of low-substituted hydroxypropyl cellulose, 1 to 15 wt% of sodium starch glycolate, 0.1 to 5 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 5 wt% of magnesium stearate, and the post-mixing portion may include, but is not limited to, 1 to 15 wt% of sodium starch glycolate, 0.1 to 5 wt% of colloidal silicon dioxide, and 0.1 to 5 wt% of magnesium stearate, based on the total weight of the first release portion.

[0200] In another example, the granules in the layer including the first release portion may include, based on the total weight of the first release portion, 10 to 80 wt% of the active ingredient, 1 to 30 wt% of microcrystalline cellulose, 1 to 20 wt% of mannitol, 5 to 30 wt% of low-substituted hydroxypropyl cellulose, 1 to 15 wt% of croscarmellose sodium, 0.1 to 5 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 5 wt% of magnesium stearate, and the post-mixing portion may include, but is not limited to, 1 to 15 wt% of croscarmellose sodium, 0.1 to 5 wt% of colloidal silicon dioxide, and 0.1 to 5 wt% of magnesium stearate, based on the total weight of the first layer.

[0201] In another example, the granules in the layer including the first release portion may include, based on the total weight of the first release portion, 10 to 80 wt% of the active ingredient, 1 to 20 wt% of microcrystalline cellulose, 1 to 20 wt% of mannitol, 5 to 20 wt% of low-substituted hydroxypropyl cellulose, 1 to 10 wt% of croscarmellose sodium, 0.1 to 5 wt% of colloidal silicon dioxide, 0.1 to 5 wt% of talc, and 0.1 to 5 wt% of magnesium stearate, and the post-mixing portion may include, but is not limited to, 1 to 10 wt% of croscarmellose sodium, 0.1 to 5 wt% of colloidal silicon dioxide, and 0.1 to 5 wt% of magnesium stearate, based on the total weight of the first layer.

[0202] In the present invention, the layer (second layer) including the second release unit may include granules containing an active ingredient and a post-mixing unit. At this time, the granules may additionally include pharmaceutically acceptable additives such as excipients, disintegrants, or lubricants. In addition, the post-mixing unit may additionally include at least one pharmaceutically acceptable additive among disintegrants and lubricants.

[0203] In one example, the layer including the second release unit may include, but is not limited to, granules including an active ingredient, an excipient, a disintegrant, and a lubricant, and a post-mix unit including the disintegrant and the lubricant.

[0204] In the present invention, the granules in the layer including the second release portion may contain the active ingredient in an amount of 0.5 to 50 wt%, 0.5 to 30 wt%, or 0.5 to 10 wt% based on the total weight of the second release portion.

[0205] In the present invention, the granules in the layer including the second release portion may contain excipients in an amount of 20 to 95 wt%, 30 to 90 wt%, 40 to 90 wt%, 50 to 80 wt%, or 60 to 80 wt% based on the total weight of the second release portion.

[0206] In the present invention, the granules in the layer including the second discharge portion may contain a disintegrant in an amount of 0.1 to 20 wt%, 1 to 10 wt%, or 2 to 8 wt% based on the total weight of the second discharge portion.

[0207] In the present invention, the granules in the layer including the second release portion may contain a lubricant in an amount of 0.1 to 20 wt%, 1 to 10 wt%, or 2 to 8 wt% based on the total weight of the second release portion.

[0208] In the present invention, the post-mixing portion within the layer including the second discharge portion may contain a disintegrant in an amount of 1 to 30 wt%, 1 to 20 wt%, 5 to 20 wt%, or 5 to 10 wt% based on the total weight of the second discharge portion.

[0209] In the present invention, the post-mixing section within the layer including the second emission section may include a lubricant in an amount of 0.1 to 20 wt%, 1 to 10 wt%, or 2 to 8 wt% based on the total weight of the second emission section.

[0210] In one example, the granules in the layer including the second release portion may include 0.5 to 50 wt% of the active ingredient, 20 to 95 wt% of the excipient, 0.1 to 20 wt% of the disintegrant, and 0.1 to 10 wt% of the lubricant, based on the total weight of the second release portion, and the post-mixing portion may include 1 to 30 wt% of the disintegrant and 0.1 to 10 wt% of the lubricant, based on the total weight of the second release portion, but is not limited thereto.

[0211] In another example, the granules in the layer including the second release portion may include 0.5 to 50 wt% of the active ingredient, 50 to 90 wt% of the excipient, 1 to 10 wt% of the disintegrant, and 1 to 10 wt% of the lubricant, based on the total weight of the second release portion, and the post-mixing portion may include 5 to 20 wt% of the disintegrant and 0.1 to 10 wt% of the lubricant, based on the total weight of the second release portion, but is not limited thereto.

[0212] In another example, the granules in the layer including the second release portion may include, based on the total weight of the second release portion, 0.5 to 50 wt% of the active ingredient, 10 to 50 wt% of at least one of microcrystalline cellulose and lactose hydrate, 10 to 50 wt% of mannitol, 0.1 to 20 wt% of hydroxypropyl cellulose, and 0.1 to 10 wt% of sodium stearyl fumarate, and the post-mixing portion may include, but is not limited to, 0.5 to 20 wt% of sodium croscarmellose and 0.1 to 10 wt% of sodium stearyl fumarate, based on the total weight of the second release portion.

[0213] In another example, the granules in the layer including the second release portion may include, based on the total weight of the second release portion, 0.5 to 50 wt% of the active ingredient, 10 to 30 wt% of microcrystalline cellulose, 20 to 70 wt% of mannitol, 0.5 to 20 wt% of hydroxypropyl cellulose, and 0.1 to 10 wt% of sodium stearyl fumarate, and the post-mixing portion may include, but is not limited to, 0.5 to 20 wt% of croscarmellose sodium and 0.1 to 10 wt% of sodium stearyl fumarate, based on the total weight of the second layer.

[0214] The combination preparation according to the present invention as described above contains two pharmacologically active ingredients, sacubitril-valsartan and an SGLT-2 inhibitor, such as dapagliflozin, in one preparation, and can be useful for the treatment or prevention of heart failure, particularly heart failure that is not sufficiently controlled with a single drug, and improves the inconvenience of having to take two preparations separately and significantly improves the convenience of taking the medication for patients. The combination preparation may be administered once a day, twice a day, three times a day, or four times a day, depending on the content of the main ingredient contained.

[0215] In addition, the combination preparation of the present invention has the advantage of having a first release portion containing sacubitril-valsartan and a second release portion containing an SGLT-2 inhibitor in the form of a bilayer tablet or a drug-coated tablet in which the first release portion containing sacubitril-valsartan and the second release portion containing the SGLT-2 inhibitor are physically separated, thereby dissolving the SGLT-2 inhibitor at a faster rate than sacubitril-valsartan, thereby preventing sacubitril-valsartan, which has low solubility in a low pH environment such as gastric acid, from inhibiting the dissolution of the SGLT-2 inhibitor, so that all of these components have a dissolution pattern in the form of an immediate release, thereby ensuring rapid and sufficient respective pharmacological effects within the administration period.

[0216] Furthermore, the combination preparation according to the present invention has a therapeutic synergy effect due to the combined use of sacubitril-valsartan and an SGLT-2 inhibitor, and has high stability by suppressing the generation of related substances.

[0217] In one example, the combination preparation according to the present invention is characterized in that the dissolution rate (by weight) of the SGLT-2 inhibitor (e.g., dapagliflozin) in a dissolution test (pH 1.2 solution, 37°C, 900 mL, 50 rpm) is 50% or more, 60% or more, 70% or more, or 80% or more within 10 minutes, 80% or more, 85% or more, or 90% or more within 15 minutes, and 85% or more, 90% or more, or 95% or more within 30 minutes.

[0218] In another example, the compound preparation according to the present invention may have a dissolution rate of sacubitril of 10 to 40% after 30 minutes and less than 50% after 2 hours in a dissolution test (pH 1.2 solution, 37°C, 900 mL, 50 rpm), but is not limited thereto.

[0219] In another example, the compound preparation according to the present invention may have a dissolution rate of valsartan of 10 to 40% after 30 minutes and less than 50% after 2 hours in a dissolution test (pH 1.2 solution, 37°C, 900 mL, 50 rpm), but is not limited thereto.

[0220] In another example, the combination preparation according to the present invention is characterized in that the dissolution rate (based on weight) of the SGLT-2 inhibitor (e.g., dapagliflozin) in a dissolution test (pH 6.8 solution, 37°C, 900 mL, 50 rpm) is 50 to 95% or 60 to 90% within 10 minutes, 80% or more, 85% or more, or 90% or more within 15 minutes, and 90% or more or 95% or more within 30 minutes.

[0221] In another example, the compound preparation according to the present invention may have a dissolution rate of sacubitril of 80% or more, 90% or more, or 95% or more within 30 minutes in a dissolution test (pH 6.8 solution, 37°C, 900 mL, 50 rpm), but is not limited thereto.

[0222] In another example, the combination preparation according to the present invention may have a dissolution rate of valsartan of 80% or more, 90% or more, or 95% or more within 30 minutes in a dissolution test (pH 6.8 solution, 37°C, 900 mL, 50 rpm), but is not limited thereto.

[0223]

[0224] According to another embodiment of the present invention, there is provided a method for preparing a compound preparation according to the present invention, comprising the following steps:

[0225] (a) a step of preparing a first release portion comprising sacubitril-valsartan or a pharmaceutically acceptable salt thereof as an active ingredient;

[0226] (b) a step of preparing a second release portion comprising an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient; and

[0227] (c) may include a step of formulating the first release portion and the second release portion into one solid formulation.

[0228] In the present invention, the composite formulation in step (c) may be formulated in the form of a bilayer tablet or multilayer tablet, or in the form of a drug-coated tablet with a core-shell structure.

[0229] In the present invention, steps (a) and (b) do not necessarily have to be performed sequentially, and step (b) may be performed after step (a), or step (a) may be performed after step (b), or steps (a) and (b) may be performed simultaneously.

[0230] In the present invention, the step of preparing the first release portion (a) may include the steps of (a-1) mixing sacubitril-valsartan or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable additive; (a-2) preparing granules; and (a-3) mixing the granules with the post-mixing portion.

[0231] In the present invention, in the step (a-1), the sacubitril or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof in the first release portion of the present invention may be included in a molar ratio of 1:5 to 5:1, preferably in a molar ratio of 1:1, but is not limited thereto.

[0232] In the present invention, the pharmaceutically acceptable additive of step (a-1) or the post-mixing part of step (a-3) may each include at least one selected from the group consisting of excipients, disintegrants, and lubricants.

[0233] In the present invention, the excipient (diluent) may be selected from the group consisting of, for example, microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminosilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose monohydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate monohydrate, calcium carbonate, sugars, and any mixture thereof, but is not limited thereto. However, in the present invention, anhydrous calcium phosphate has poor compatibility with dapagliflozin and sacubitril-valsartan, and therefore is not included as an excipient (diluent).

[0234] In the present invention, the disintegrant may be selected from the group consisting of, for example, crospovidone, methylcellulose, cross-linked carboxymethylcellulose sodium (Cross-linked CMC Na, C.CMC Na, or croscarmellose sodium), carboxymethylcellulose calcium, sodium starch glycolate, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, alginic acid or its sodium salt, and any combination thereof, but is not limited thereto.

[0235] In the present invention, the lubricant may be selected from the group consisting of, but is not limited to, calcium stearate, colloidal silicon dioxide (fumed silica, Aerosil), glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid, hardened vegetable oil, polyethylene glycol, sodium benzoate, talc, and any combination thereof.

[0236] In one example, in the step (a-1), granules can be manufactured by adjusting and mixing sacubitril and valsartan or a pharmaceutically acceptable salt thereof as active ingredients and an additive selected from among microcrystalline cellulose, mannitol, low-substituted hydroxypropyl cellulose (L-HPC), croscarmellose sodium, sodium starch glycolate, colloidal silicon dioxide (fumed silica, Aerosil), talc, magnesium stearate, and any combination thereof as pharmaceutically acceptable additives in an appropriate amount.

[0237] In another example, the step (a-1) may include sacubitril and valsartan or a pharmaceutically acceptable salt thereof as active ingredients, and an additive selected from among microcrystalline cellulose, mannitol, low-substituted hydroxypropyl cellulose (L-HPC), croscarmellose sodium, colloidal silicon dioxide (fumed silica, Aerosil), talc, magnesium stearate, and any combination thereof as pharmaceutically acceptable additives.

[0238] In another example, the step (a-1) may include sacubitril and valsartan or a pharmaceutically acceptable salt thereof as active ingredients, and an additive selected from among microcrystalline cellulose, low-substituted hydroxypropyl cellulose (L-HPC), sodium starch glycolate, colloidal silicon dioxide (fumed silica, Aerosil), talc, magnesium stearate, and any combination thereof as pharmaceutically acceptable additives.

[0239] In the present invention, the (a-2) granule manufacturing step may be manufactured according to any granule manufacturing method known in the art, and may be manufactured, for example, by a dry granulation method. Specifically, a mixture of sacubitril and valsartan or a pharmaceutically acceptable salt thereof as active ingredients and pharmaceutically acceptable additives such as excipients, disintegrants, or lubricants may be granulated using a roller compacting method or a slugging method. Here, roller compaction refers to a method of manufacturing granules by compressing powders at a constant pressure while passing them between two rollers. The roller compaction method may be performed using a roller compactor. The roller-compacted mixture may then be further subjected to a process of pulverizing and sizing using a fitzmill, an oscillator, or the like, as necessary, to obtain granules of an appropriate size.

[0240] In the present invention, in the step (a-3), the post-mixing unit may include a disintegrant, a lubricant, or a mixture thereof, and may additionally include an excipient (diluent) or a binder, if necessary.

[0241] In one example, in the step (a-3), the granules obtained in the step (a-2) and a post-mixing portion including sodium starch glycolate, colloidal silicon dioxide (fumed silica, Aerosil), and magnesium stearate can be adjusted and mixed in an appropriate amount.

[0242] In the present invention, depending on the formulation of the final composite preparation, a step of tableting (a-4) may be additionally included after step (a-3).

[0243] In the present invention, the step (a-4) may be performed using a tableting machine commonly used for tableting granules, for example, a rotary tableting machine.

[0244] In the present invention, the tablet obtained after the pressing in the step (a-4) can be manufactured in various shapes, for example, oval, rectangular, egg-shaped, triangular, almond-shaped, peanut-shaped, parallelogram-shaped, circular, pentagonal, hexagonal or trapezoidal, preferably circular, egg-shaped or parallelogram-shaped.

[0245] In the present invention, the content of each component mixed during the manufacture of the first release portion overlaps with that described in the first layer of the composite preparation according to the present invention, and thus, in order to avoid excessive complexity of the specification, a detailed description thereof is omitted below.

[0246] In the present invention, the step of manufacturing the second release portion (b) may include the step of mixing (b-1) an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive.

[0247] In the present invention, the pharmaceutically acceptable additive of step (b-1) may be at least one selected from the group consisting of excipients, disintegrants, and lubricants.

[0248] In the present invention, the excipient (diluent) may be selected from the group consisting of, for example, microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminosilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose monohydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate monohydrate, calcium carbonate, sugars, and any mixture thereof, but is not limited thereto. However, in the present invention, anhydrous calcium phosphate has poor compatibility with dapagliflozin and sacubitril-valsartan, and therefore is not included as an excipient (diluent).

[0249] In the present invention, the disintegrant may be selected from the group consisting of, for example, crospovidone, methylcellulose, cross-linked carboxymethylcellulose sodium (Cross-linked CMC Na, C.CMC Na, or croscarmellose sodium), carboxymethylcellulose calcium, sodium starch glycolate, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, alginic acid or its sodium salt, and any combination thereof, but is not limited thereto.

[0250] In the present invention, the lubricant may be selected from the group consisting of, but is not limited to, calcium stearate, colloidal silicon dioxide (fumed silica, Aerosil), glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid, hardened vegetable oil, polyethylene glycol, sodium benzoate, talc, and any combination thereof.

[0251] In one example, when the final manufactured combination preparation is a bilayer tablet, in step (b-1), an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient and an additive selected from among microcrystalline cellulose, lactose monohydrate, mannitol, hydroxypropyl cellulose, sodium stearyl fumarate, sodium croscarmellose, and any combination thereof as pharmaceutically acceptable additives can be adjusted and mixed in an appropriate amount.

[0252] In one example, when the final manufactured combination preparation is a bilayer tablet, in step (b-1), an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient and an additive selected from among microcrystalline cellulose, mannitol, hydroxypropyl cellulose, sodium stearyl fumarate, sodium croscarmellose, and any combination thereof as a pharmaceutically acceptable additive can be adjusted and mixed in an appropriate amount.

[0253] In addition, in the present invention, when the final manufactured composite formulation is a two-layer tablet, the step (b-1) may include a step of manufacturing granules (b-2); and a step (b-3) of mixing the granules with the post-mixing portion.

[0254] In the present invention, the post-mixing portion of step (b-3) may include a disintegrant, a lubricant, or a mixture thereof, and may additionally include an excipient (diluent) or a binder, if necessary.

[0255] In one example, in the step (b-3), the granules obtained in the step (b-2) and the post-mixed portion including sodium stearyl fumarate and sodium croscarmellose can be adjusted and mixed in an appropriate amount.

[0256] In the present invention, in order to manufacture a composite preparation in the form of a two-layer tablet in the step (c), the mixed powder of the first release portion obtained in the step (a-3) (mixture of granules and post-mixed portion) and the mixed powder of the second release portion obtained in the step (b-3) (mixture of granules and post-mixed portion) may be pressed into a tablet press to form the upper layer mixed powder and the lower layer mixed powder of the two-layer tablet, or conversely, the lower layer mixed powder and the upper layer mixed powder, respectively, to manufacture the two-layer tablet.

[0257] Meanwhile, in the present invention, when the final manufactured composite formulation is a drug-coated tablet, a coating solution can be manufactured by adjusting and mixing an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient and a coating agent in an appropriate amount in step (b-1).

[0258] In the present invention, the coating agent is a hydrophilic polymer, for example, hydroxypropylmethyl cellulose (HPMC), polyvinyl alcohol (PVA), macrogol polyvinyl alcohol graft copolymer, polymers of acrylic acid and its salts, polymethacrylate, poly(butyl methacrylate, 2-dimethylaminoethyl methacrylate, methyl methacrylate) copolymers (e.g., Eudragit® E, Evonik), carboxymethylcellulose (sodium salt and calcium salt), ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethyl cellulose, hydroxypropylcellulose (HPC), L-HPC (low-substituted HPC), polyvinylpyrrolidone (povidone; PVP), vinylpyrrolidone-vinylacetate copolymers (e.g., Kollidon® VA64, The coating material may be at least one selected from the group consisting of BASF, gelatin, guar gum, partially hydrolyzed starch, alginate, xanthan, and mixtures thereof, but is not limited thereto. Preferably, the coating material may be hydroxypropylmethylcellulose (HPMC), polyvinyl alcohol (PVA), macrogol polyvinyl alcohol graft copolymer, poly(butyl methacrylate, 2-dimethylaminoethyl methacrylate, methyl methacrylate) copolymer (e.g., Eudragit® E, Evonik).

[0259] In addition, the coating solvent used in the preparation of the coating solution in the present invention may be ethanol, methanol, acetone, acetonitrile, tetrahydrofuran, hexane, methylene chloride, isopropyl alcohol, water, or a mixed solvent thereof. Preferably, ethanol, water, or a mixture thereof may be used.

[0260] In the present invention, when preparing the coating solution, for additional purposes such as improving coating efficiency, drug stability, appearance, color, protection, maintenance, binding, performance, and manufacturing process, one or more selected from the group consisting of plasticizers, lubricants, colorants, flavoring agents, surfactants, stabilizers, antioxidants, foaming agents, antifoaming agents, paraffin, and waxes may be additionally mixed and used.

[0261] In the step (c) of the present invention, in order to manufacture a combination preparation in the form of a drug-coated tablet, a core containing sacubitril-valsartan or a pharmaceutically acceptable salt thereof obtained in the step (a) as an active ingredient, preferably a core in the form of a tablet obtained in the step (a-4), is coated with the coating solution of the second release portion obtained in the step (b-1) to manufacture a drug-coated tablet in which an SGLT-2 inhibitor drug is coated on the core of sacubitril-valsartan. Here, the coating can be performed using a conventional method used in the art for coating drugs, and for example, a coating method using a pan coater can be used, but is not limited thereto.

[0262] In one example of the manufacturing method, a method for manufacturing a combination preparation in the form of a bilayer tablet may include the steps of: (a-1) mixing sacubitril and valsartan or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; (a-2) preparing granules; (a-3) mixing a post-mixing portion to prepare a mixed powder of a first release portion; (b-1) mixing an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient; (b-2) preparing granules; (b-3) mixing a post-mixing portion to prepare a mixed powder of a second release portion; and (c) compressing the mixed powder of the first release portion and the mixed powder of the second release portion to prepare a bilayer tablet. However, the order of performing steps (a-1), (a-2), (a-3), (b-1), (b-2), and (b-3) is not particularly limited.

[0263] In another example of the manufacturing method, a method for manufacturing a combination preparation in the form of a drug-coated tablet may include the steps of: (a-1) mixing sacubitril and valsartan or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive; (a-2) preparing granules; (a-3) mixing a post-mixing portion to prepare a mixed powder of a first release portion; (a-4) compressing the mixed powder of the first release portion to prepare a naked tablet; (b-1) mixing an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof and a coating agent to prepare a coating solution; and (c) coating the coating solution on the surface of a naked tablet including the first release portion to prepare a drug-coated tablet. However, the order of performing steps (a-1), (a-2), (a-3), (a-4), and (b-1) is not particularly limited.

[0264] The manufacturing method of the present invention may further include a step of coating the obtained composite formulation, particularly in the form of a bilayer tablet, with a pharmaceutical rapid-release film coating agent commonly used in the art, according to a conventional method. In one example, a moisture-proof film coating may be performed at about 3% with an Opadry II coating solution based on the total weight of the uncoated tablet of the bilayer tablet, but is not limited thereto.

[0265]

[0266] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.

[0267]

[0268] Example

[0269]

[0270] [Comparative Examples 1 and 2] Preparation of single-layer tablets containing sacubitril-valsartan and dapagliflozin

[0271] In order to manufacture a single combination tablet in which sacubitril-valsartan and dapagliflozin are physically mixed, sacubitril-valsartan, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, sodium starch glycolate, colloidal silicon dioxide, talc, and magnesium stearate are mixed according to the composition shown in Table 1 below, and compressed using a roller compactor (TFC-LAB, Freund vector) under the conditions of 5 MPa of hydraulic pressure, 1 rpm of roller speed, and 5 rpm of screw speed to form dry granules, and then sieved through a sieve with a 20 mesh (0.86 mm) mesh size, and then post-mixed with sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate to manufacture a final mixed powder, during the process of manufacturing the dry granules (Comparative Example 1) or during the post-mixing process (Comparative Example 2). The final mixture was prepared by adding dapagliflozin, microcrystalline cellulose, D-mannitol, hydroxypropyl cellulose, croscarmellose sodium, and sodium stearyl fumarate. Then, using a tableting machine (AUTOTAB-200TR, Ichihashi Seiki), a single-layer tablet with a hardness of approximately 15 kPa was prepared at a compression pressure of 10 kN.

[0272] Process ingredient content (mg / tablet) Comparative example 1 Comparative example 2 Mixed tablet (simultaneous granulation) Mixed tablet (post-mixing) Compacted Sacubitril-Valsartan trisodium trihydrate 228.34 228.34 Dapagliflozin propanediol 12.30 - Microcrystalline cellulose 53.66 53.66 Low-substituted hydroxypropyl cellulose 50.00 50.00 Sodium starch glycolate 20.00 20.00 Colloidal silicon dioxide 1.60 1.60 Talc 4.00 4.00 Magnesium stearate 6.00 6.00 Final mixture Dapagliflozin propanediol-12.30 Sodium starch glycolate 20.00 20.00 Colloidal silicon dioxide 2.40 2.40 Magnesium stearate 4.00 4.00

[0273]

[0274] [Examples 1 to 2] Preparation of a bilayer tablet containing sacubitril-valsartan and dapagliflozin

[0275] Sacubitril-valsartan, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, sodium starch glycolate, colloidal silicon dioxide, talc, and magnesium stearate were mixed according to the composition shown in Table 2 below, and compressed using a roller compactor (TFC-LAB, Freund Vector) at 5 MPa of hydraulic pressure, 1 rpm of roller speed, and 5 rpm of screw speed to form dry granules, which were then sieved through a 20 mesh (0.86 mm) mesh sieve. Here, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate were post-mixed to prepare the final sacubitril-valsartan mixed powder. And dapagliflozin, microcrystalline cellulose, lactose hydrate, D-mannitol, hydroxypropyl cellulose. Croscarmellose sodium and sodium stearyl fumarate were mixed and compressed using a roller compactor (TFC-LAB, Freund Vector) at 5 MPa of hydraulic pressure, 1 rpm of roller speed, and 5 rpm of screw speed to form dry granules, which were then sieved through a sieve with a mesh size of 20 mesh (0.86 mm). Sodium stearyl fumarate was then mixed in to prepare the final dapagliflozin mixture. The final sacubitril-valsartan mixture was used as the lower layer, and the final dapagliflozin mixture was used as the upper layer. The tablets were compressed into two-layer tablets (hardness of approximately 15 KP) using an oval punch measuring 17.5 mm in width and 9 mm in length using an Autotab-200TR, Ichihashi Seiki at a compression pressure of 10 KN.

[0276] Process Prescription Amount (mg / tablet)Example 1Example 2Bilayer tablet (microcrystalline cellulose)Bilayer tablet (lactose hydrate)Sacubitril-valsartan compactingSacubitril-valsartan trisodium trihydrate228.34228.34Microcrystalline cellulose53.6653.66Low-substituted hydroxypropyl cellulose50.0050.00Sodium starch glycolate20.0020.00Colloidal silicon dioxide1.601.60Talc4.004.00Magnesium stearate6.006.00Final mixingSodium starch glycolate20.0020.00Colloidal silicon dioxide2.402.40Magnesium stearate4.004.00Total amount390390Dapagliflozin compactingDapagliflozin Propanediol 12.30 12.30 Microcrystalline cellulose 99.10 - Lactose monohydrate - 99.10 Anhydrous calcium phosphate - D-mannitol 90.00 90.00 Hydroxypropyl cellulose 10.00 10.00 Sodium stearyl fumarate 12.00 12.00 Final mixture Croscarmellose sodium 20.00 20.00 Sodium stearyl fumarate 8.00 8.00 Total 251.4 251.4

[0277]

[0278] [Example 3] Preparation of drug-coated tablets containing sacubitril-valsartan and dapagliflozin

[0279] The final mixture of sacubitril-valsartan was prepared in the same manner as in Example 1, and then compressed into tablets using a tablet press to produce uncoated tablets. To prepare a drug coating solution, a coating solution containing dapagliflozin, povidone, and macrogol-polyvinyl alcohol copolymer was prepared in 200 mg of purified water and 200 mg of ethanol per 1T with the composition shown in Table 3 below. Thereafter, the coating solution was coated onto the surface of the uncoated tablets using a high-speed coalescer (XENA-IV, Raon) under the conditions of a supply air temperature of 55°C, a non-supply air temperature of 45°C, a fan speed of 6 rpm, and an air pressure gauge of 2 to 4 kgf / cm2.

[0280] Process prescription amount (mg / tablet) Example 3 Drug-coated tablets Sacubitril-valsartan compacted Sacubitril-valsartan trisodium trihydrate 228.34 Microcrystalline cellulose 53.66 Low-substituted hydroxypropyl cellulose 50.00 Sodium starch glycolate 20.00 Colloidal silicon dioxide 1.60 Talc 4.00 Magnesium stearate 6.00 Final mixed sodium starch glycolate 20.00 Colloidal silicon dioxide 2.40 Magnesium stearate 4.00 Total amount 390 Dapagliflozin Drug-coated tablets Dapagliflozin Propanediol 12.30 Povidone 2.80 Macrogol-polyvinyl alcohol copolymer 20.00 Total amount 35.1

[0281]

[0282] [Comparative Example 3] Preparation of cored tablets containing sacubitril-valsartan and dapagliflozin

[0283] The final mixture of sacubitril-valsartan for the inner core tablet and the final mixture of dapagliflozin for the outer core tablet were prepared using the same composition as in Example 1. The final mixture of sacubitril-valsartan was compressed into tablets using a tablet press to produce inner core tablets. Half of the filling amount of the final mixture of dapagliflozin and the inner core tablet were sequentially filled, and then the remaining final mixture of dapagliflozin was filled and pressure was applied to produce cored tablets. The compression pressure was adjusted to 7 to 10 kN, and no preload was applied.

[0284]

[0285] [Comparative Example 4] Preparation of polycaps containing sacubitril-valsartan tablets and dapagliflozin tablets

[0286] The final mixed powder of sacubitril-valsartan and the final mixed powder of dapagliflozin were prepared with the same composition as in Example 1. The final mixed powder of sacubitril-valsartan and the final mixed powder of dapagliflozin were each compressed into a tablet machine to produce two single-layer tablets. Capsules were prepared by filling these two tablets into one capsule using a polycap filling machine (GKF2500, Bosch) under the conditions of an air pressure of 5 to 7 bar and a filling speed of 30 to 150 C / min. HPMC capsules with a moisture content of about 3 to 7%, gelatin with a moisture content of about 13 to 16%, and gelatin-PEG with a moisture content of about 10 to 14% were used as capsule bases.

[0287]

[0288] [Comparative Example 5] Change in the composition of excipients in a bilayer tablet containing sacubitril-valsartan and dapagliflozin

[0289] In order to confirm the dissolution pattern or stability change of the composite tablet according to the excipient component, a bilayer tablet was prepared using the same manufacturing method as Example 1, but the microcrystalline cellulose used as an excipient in the final mixture of dapagliflozin was changed to anhydrous calcium phosphate as shown in Table 4 below to prepare a bilayer tablet.

[0290] Fair prescription dosage (mg / tablet) Comparative example 5 Bilayer tablet (anhydrous calcium phosphate) Sacubitril-valsartan compacting Sacubitril-valsartan trisodium trihydrate 228.34 Microcrystalline cellulose 53.66 Low-substituted hydroxypropyl cellulose 50.00 Sodium starch glycolate 20.00 Colloidal silicon dioxide 1.60 Talc 4.00 Magnesium stearate 6.00 Final mixing Sodium starch glycolate 20.00 Colloidal silicon dioxide 2.40 Magnesium stearate 4.00 Total 390 Dapagliflozin compacting Dapagliflozin Propanediol 12.30 Microcrystalline cellulose-lactose monohydrate-anhydrous calcium phosphate 99.10 D-mannitol 90.00 Hydroxypropyl cellulose 10.00 Sodium stearyl fumarate 12.00 Final mixture croscarmellose sodium 20.00 Sodium stearyl fumarate 8.00 Total 251.4

[0291]

[0292] [Experimental Example 1] Dissolution Evaluation by Compound Preparation

[0293] Both sacubitril-valsartan and dapagliflozin have rapid absorption rates, with a Tmax of less than 2 hours after administration, and high bioavailability of approximately 80%. While dapagliflozin has high solubility at all pH levels, sacubitril-valsartan has a characteristic of decreasing solubility as the pH decreases. Considering these characteristics, the following experiment was conducted to determine whether both components ensured rapid release in pH 1.2 and pH 6.8 solutions, thereby securing a dissolution profile similar to that of the reference drug.

[0294] Specifically, the dissolution evaluation of dapagliflozin, sacubitril and valsartan was performed in the combination preparation containing 10 mg of dapagliflozin and 200 mg of sacubitril-valsartan prepared in Examples 1 to 3 and Comparative Examples 1 to 5. Considering the location and rate of drug absorption, the comparison of drug release at low pH and high pH was performed under the following test and analysis conditions. The dissolution rate of each component in the combination preparation in pH 1.2 solution and pH 6.8 solution was compared with the single-drug control drug, PosiGajeong. TM (Dapagliflozin propanediol hydrate) 10 mg, Entresto tablets TM The results are shown in Tables 5 to 10 and Figures 1 to 6, compared to (sacubitril / valsartan) 200 mg.

[0295] <Dissolution test conditions>

[0296] Dissolution test solution: pH 1.2 buffer (900mL), pH 6.8 buffer (900mL)

[0297] Dispensing device: Paddle

[0298] Rotation speed: 50rpm

[0299] Temperature: 37℃

[0300] <Analysis Conditions - LC>

[0301] Column: Inertsil C8 (4.6 x 150 mm, 5 μm) or equivalent column

[0302] Flow rate: 1.5ml / min

[0303] Column temperature: 40℃

[0304] Injection volume: 20 μL

[0305] Mobile phase: pH2.0 buffer: ACN = 60:40

[0306] pH2.0 buffer: Dissolve 3.48g of potassium dihydrogen phosphate in 1000mL and adjust pH to 2.0 with phosphoric acid.

[0307] Dissolution rate (%) of dapagliflozin over time in pH 1.2 solutionDissolution rate (%)Comparative Example 1Comparative Example 2Comparative Example 3Comparative Example 4Comparative Example 5Example 1Example 2Example 3Control Example0 min0.00.00.00.00.00.00.00.05 min0.01.158.220.021.165.260.173.566.810 min0.52.573.235.239.290.587.29 6.294.615 minutes 1.23.886.548.253.295.192.198.198.230 minutes 1.95.288.168.272.798.195.399.098.545 minutes 3.77.291.278.185.798.996.199.299.1f2 (similarity factor) 45462020816476-

[0308] Dissolution rate (%) of sacubitril over time in pH 1.2 solutionDissolution rate (%)Comparative Example 1Comparative Example 2Comparative Example 3Comparative Example 4Comparative Example 5Example 1Example 2Example 3Control Example0 min0.00.00.00.00.00.00.00.00.05 min1.12.10.51.51.02.30.80.70.610 min1.53.24.04.29.37.45.26.06.3 15 minutes 2.54.58.010.021.313.610.011.012.030 minutes 3.76.713.321.338.830.122.326.025.345 minutes 5.48.918.227.142.938.028.732.033.8f2(similarity factor)4144547355767894-

[0309] Dissolution rate (%) of valsartan over time in a pH 1.2 solutionDissolution rate (%)Comparative Example 1Comparative Example 2Comparative Example 3Comparative Example 4Comparative Example 5Example 1Example 2Example 3Control Example0 min0.00.00.00.00.00.00.00.00.05 min1.02.20.11.82.42.50.70.30.610 min1.93.31.15.28.87.94.85.05. 515 minutes 2.74.21.511.819.614.511.09.210.530 minutes 3.86.61.322.536.131.123.026.122.645 minutes 5.38.82.129.241.038.429.133.030.3f2(similarity factor)4447419454649683-

[0310] Dissolution rate (%) of dapagliflozin over time in a pH 6.8 solutionDissolution rate (%)Comparative Example 1Comparative Example 2Comparative Example 3Comparative Example 4Comparative Example 5Example 1Example 2Example 3Control Example0 min0.00.00.00.00.00.00.00.00.05 min26.830.240.025.124.247.140.571.248.010 min47.051.075.335.138.482.179.188. 981.615 minutes 60.363.282.347.548.593.090.495.292.030 minutes 71.574.886.165.267.597.194.298.098.245 minutes 74.078.090.167.169.799.096.799.098.6f2 (similarity factor) 2932542425957050-

[0311] Dissolution rate (%) of sacubitril over time in a pH 6.8 solutionDissolution rate (%)Comparative Example 1Comparative Example 2Comparative Example 3Comparative Example 4Comparative Example 5Example 1Example 2Example 3Control Example0 min0.00.00.00.00.00.00.00.00.05 min32.828.113.216.715.220.115.118.119.810 min53.648.530.543.240.150.343.246. 249.115 minutes 76.463.247.268.265.072.166.067.071.030 minutes 82.772.191.987.281.298.195.296.097.945 minutes 87.475.995.791.386.099.297.197.298.9f2 (similarity factor) 5041446050967079-

[0312] Dissolution rate (%) of valsartan over time in pH 6.8 solutionDissolution rate (%)Comparative Example 1Comparative Example 2Comparative Example 3Comparative Example 4Comparative Example 5Example 1Example 2Example 3Control Example0 min0.00.00.00.00.00.00.00.00.05 min32.627.114.517.116.117.114.119.120.410 min54.049.232.244.142.144.144.247. 349.715 minutes 69.864.249.569.667.169.665.068.271.730 minutes 82.873.192.388.383.588.396.196.598.745 minutes 87.977.296.193.289.293.298.196.999.7f2 (similarity factor) 5142466253626783-

[0313]

[0314] As shown in Tables 5 to 10 above, in Comparative Examples 1 and 2, which are single-layer tablets containing sacubitril-valsartan and dapagliflozin physically mixed, sacubitril-valsartan and dapagliflozin were released simultaneously. It was confirmed that in the process of dissolving the two components simultaneously in the pH 1.2 and pH 6.8 solutions, they changed into sticky states, inhibiting each other's dissolution, and thus delaying the dissolution. In particular, in the pH 1.2 solution, the dissolution rate of both components was confirmed to be 10% or less after 45 minutes.

[0315] In the case of the cored tablet of Comparative Example 3, which was designed to distribute sacubitril-valsartan in the inner core layer and dapagliflozin in the outer core layer, since the disintegration of the inner core layer began after the disintegration of the outer core layer, a fast dissolution profile similar to the control was confirmed for the dissolution rate of dapagliflozin present in the outer core layer, but a relatively slow dissolution profile was confirmed for sacubitril-valsartan present in the inner core layer compared to the control drug.

[0316] In the case of the polycap of Comparative Example 4, which filled a single tablet of sacubitril-valsartan and a single tablet of dapagliflozin into one capsule, tablet disintegration began after the capsule was dissolved, so the dissolution rate at 5 or 10 minutes was relatively slow compared to the control drug, and the dissolution rate gradually increased after 15 minutes, but the dissolution rate of dapagliflozin was only at a significantly lower level than the control drug even after 45 minutes in both the pH 1.2 and pH 6.8 solutions.

[0317] Meanwhile, in the case of the bilayer tablets of Examples 1 and 2, in which sacubitril-valsartan and dapagliflozin were each positioned in separate layers, a dissolution profile similar to that of the reference drug was confirmed for all components of sacubitril, valsartan, and dapagliflozin in pH 1.2 and pH 6.8 solutions. However, in the case of the bilayer tablet of Comparative Example 5, which used anhydrous calcium phosphate as an excipient, unlike the microcrystalline cellulose of Example 1 or the lactose hydrate of Example 2, a dissolution profile in which the disintegration of the dapagliflozin tablet portion was relatively slower than that of the reference drug was confirmed due to the water-insoluble and high-density nature of anhydrous calcium phosphate.

[0318] In the case of the drug-coated tablet of Example 3, in which the core of sacubitril-valsartan was drug-coated with dapagliflozin, the initial dissolution rate at 5 or 10 minutes was found to be somewhat faster than that of the control drug because the time at which dapagliflozin meets the dissolution test solution was the fastest, but a similar dissolution profile was confirmed at subsequent time points, and sacubitril and valsartan showed similar dissolution profiles to the control drug under all conditions of pH 1.2 and pH 6.8 solutions.

[0319]

[0320] [Experimental Example 2] Flexible Stability Evaluation by Compound Preparation

[0321] Sacubitril-valsartan has relatively heat and moisture stability and good compatibility with commonly used excipients. However, dapagliflozin has more than 80 known types of flexible substances, so there is a high possibility that its structure may be modified by external factors. Therefore, it is essential to confirm the stability of flexible substances of dapagliflozin when developing a formulation.

[0322] Accordingly, a flexible stability evaluation was conducted on the composite formulations manufactured in Examples 1 to 3 and Comparative Examples 1 to 5. The increase trend of the flexible substances of dapagliflozin in the samples manufactured by each type of formulation and excipient was evaluated by exposing them to accelerated conditions (40°C, 75% RH) and harsh conditions (60°C) for 2 weeks, and the results are shown in Figures 7 to 10. The analysis conditions for the flexible substances are as follows. As a control example, Posi-ga-jeong TM (Dapagliflozin propanediol hydrate) The results of the analysis of flexible substances for 10 mg were presented.

[0323] <Analysis Conditions - LC>

[0324] Column: Waters X-Bridge C18 (4.6 x 150 mm, 3.5 μm) or equivalent column

[0325] Flow rate: 1.0ml / min

[0326] Column temperature: 50 ℃

[0327] Injection volume: 10 μL

[0328] Mobile phase: A - ACN: pH2.5 buffer = 10: 90, B - MeOH: pH2.5 buffer = 90: 10

[0329] pH2.5 buffer: Dissolve 3.12g of monosodium phosphate dihydrate in 1000mL and adjust the pH to 2.5 with phosphoric acid.

[0330] Time (minutes)A (%)B (%)0604056040404060502575582575606040706040

[0331] As shown in Figures 7 to 10, in Comparative Examples 1 and 2, which are mixed single tablets, sacubitril-valsartan and dapagliflozin are not separated but exist while affecting each other. It was confirmed that sacubitril-valsartan, which has a high moisture absorption property when exposed to accelerated conditions, absorbs moisture and affects dapagliflozin, resulting in an increase in the level of generation of unknown related substances (RRT 1.59) generated by moisture under accelerated exposure conditions.

[0332] In the case of the cored tablet of Comparative Example 3, dapagliflozin is compressed into an outer core layer that surrounds the inner core layer. At this time, since high compression pressure is transmitted in all directions to maintain the shape, an unknown flexible substance (RRT 0.38) that shows an increase pattern due to heat was detected at a high level from the beginning, and showed a pattern of further increase upon acceleration and harsh exposure.

[0333] Meanwhile, in the case of the bilayer tablets of Examples 1 and 2, it was confirmed that the stability of the flexible substance was generally good. However, in the case of the bilayer tablet of Comparative Example 5, which used anhydrous calcium phosphate as an excipient, the mixing compatibility of dapagliflozin and anhydrous calcium phosphate was not good, and as a result, the unknown flexible substance (RRT 0.74) increased significantly when exposed to moisture and heat, and it was confirmed that the increase due to heat was even greater.

[0334] In the case of the drug-coated tablet of Example 3, since dapagliflozin is partially exposed to heat during the drug coating process, the detection level of the unknown active substance (RRT 0.74) tends to be slightly higher, but it can be confirmed that the detection amount is very low compared to the cored tablet of Comparative Example 3.

[0335]

[0336] [Example 4] Preparation of a bilayer tablet containing sacubitril-valsartan and dapagliflozin

[0337] Sacubitril-valsartan, microcrystalline cellulose, D-mannitol, low-substituted hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, talc, and magnesium stearate were mixed according to the composition shown in Table 12 below and placed in a roller compactor to prepare dry granules. Croscarmellose sodium and colloidal silicon dioxide were mixed to prepare a second mixed powder, and then magnesium stearate was post-mixed to prepare a sacubitril-valsartan final mixed powder (first mixed powder). Then, dapagliflozin propanediol, microcrystalline cellulose, D-mannitol, hydroxypropyl cellulose, croscarmellose sodium, and sodium stearyl fumarate were mixed and placed in a roller compactor to prepare dry granules. Afterwards, croscarmellose sodium was mixed into the granules to produce a secondary mixed powder, and then sodium stearyl fumarate was post-mixed to produce the final mixed powder of dapagliflozin (second mixed powder). The final mixed powder of sacubitril-valsartan was placed as the lower layer, and the final mixed powder of dapagliflozin was placed as the upper layer. The tablets were compressed into two-layer tablets (hardness of approximately 15 KP) using an oval punch measuring 17.5 mm in width and 9 mm in length using a tableting machine (Autotab-200TR, Ichihashi Seiki) at a compression pressure of 10 KN.

[0338] Process prescription amount (mg / tablet) Example 4 Bilayer tablet (microcrystalline cellulose) Sacubitril-valsartan (lower layer) Dry granules Sacubitril-valsartan trisodium trihydrate 228.3 Microcrystalline cellulose 25.0 D-mannitol 19.7 Low-substituted hydroxypropyl cellulose 59.0 Croscarmellose sodium 20.0 Colloidal silicon dioxide 1.5 Talc 4.0 Magnesium stearate 6.0 Secondary mixed croscarmellose sodium 20.0 Colloidal silicon dioxide 2.5 Final mixed magnesium stearate 4.0 Total 390 Dapagliflozin (upper layer) Compacted dapagliflozin Propanediol 12.3, Microcrystalline Cellulose 39.4, D-Mannitol 113.6, Hydroxypropyl Cellulose 10.0, Sodium Stearyl Fumarate 8.4, Secondary Mixed Sodium Croscarmellose 20.0, Final Mixed Sodium Stearyl Fumarate 6.3, Total 210

[0339]

[0340] [Experimental Example 3] Evaluation of dissolution of a two-layer tablet

[0341] In order to evaluate the dissolution ability of each active ingredient in the bilayer tablets of sacubitril-valsartan and dapagliflozin manufactured in Example 4, the dissolution profile was confirmed in a pH 1.2 solution using the same method as Experimental Example 1, and the results are shown in Tables 13 to 15 below.

[0342] pH 1.2 solution Dapagliflozin Example 45 min Dissolution rate (%) (min~max) 44.0 (38.8~50.8) Deviation (%) 5.0 10 min Dissolution rate (%) (min~max) 74.8 (71.2~80.9) Deviation (%) 4.2 15 min Dissolution rate (%) (min~max) 84.8 (80.2~92.6) Deviation (%) 5.4 30 min Dissolution rate (%) (min~max) 96.5 (94.2~98.5) Deviation (%) 1.8 45 min Dissolution rate (%) (min~max) 97.5 (95.3~99.1) Deviation (%) 1.7

[0343] pH 1.2 solution Sacubitril Example 45 min Dissolution rate (%) (min~max) 3.8 (2.1~4.7) Deviation (%) 1.2 10 min Dissolution rate (%) (min~max) 10.1 (7.4~11.6) Deviation (%) 1.9 15 min Dissolution rate (%) (min~max) 16.4 (14.0~19.1) Deviation (%) 2.1 30 min Dissolution rate (%) (min~max) 27.6 (26.2~29.7) Deviation (%) 1.7 45 min Dissolution rate (%) (min~max) 33.5 (32.0~34.4) Deviation (%) 1.1

[0344] pH 1.2 solution Valsartan Example 45 min Dissolution rate (min~max) 4.1 (1.8~4.5) Deviation 1.1 10 min Dissolution rate (min~max) 9.8 (7.3~11.4) Deviation 1.8 15 min Dissolution rate (min~max) 15.3 (13.8~18.7) Deviation 2.0 30 min Dissolution rate (min~max) 28.2 (27.1~30.2) Deviation 1.8 45 min Dissolution rate (min~max) 34.1 (33.1~34.5) Deviation 1.3

[0345] As shown in Tables 13 to 15 above, in the case of the bilayer tablet of Example 4, in which sacubitril-valsartan and dapagliflozin were each positioned in separate layers, an excellent dissolution profile was shown for all components of sacubitril, valsartan, and dapagliflozin in a pH 1.2 solution.

[0346]

[0347] [Examples 5 and 6] Preparation of bilayer tablets containing sacubitril-valsartan and dapagliflozin

[0348] Sacubitril-valsartan, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, sodium starch glycolate, colloidal silicon dioxide, talc, and magnesium stearate were mixed according to the composition shown in Table 16 below, and compressed using a roller compactor (TFC-LAB, Freund Vector) at 5 MPa of hydraulic pressure, 1 rpm of roller speed, and 5 rpm of screw speed to form dry granules, which were then sieved through a 20 mesh (0.86 mm) mesh sieve. Here, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate were post-mixed to prepare the final sacubitril-valsartan mixed powder. And dapagliflozin, microcrystalline cellulose, lactose hydrate, D-mannitol, hydroxypropyl cellulose. Croscarmellose sodium and sodium stearyl fumarate were mixed and compressed using a roller compactor (TFC-LAB, Freund Vector) at 5 MPa of hydraulic pressure, 1 rpm of roller speed, and 5 rpm of screw speed to form dry granules, which were then sieved through a sieve with a mesh size of 20 mesh (0.86 mm). Sodium stearyl fumarate was then mixed in to prepare the final dapagliflozin mixture. The sacubitril-valsartan final mixture was the lower layer, and the dapagliflozin final mixture was the upper layer. The sacubitril-valsartan final mixture was compressed into a tablet machine (Autotab-200TR, Ichihashi Seiki) with an oval punch measuring 17.5 mm in width and 9 mm in length at a compression pressure of 10 KN to prepare a double-layer tablet (hardness of approximately 15 KP).

[0349] Process Prescription Amount (mg / tablet) Example 5 Example 6 Sacubitril-Valsartan Compacting Sacubitril-Valsartan Trisodium 2.5 Hydrate 226.2 226.2 Microcrystalline Cellulose 55.8 55.8 Low-Substituted Hydroxypropyl Cellulose 50.00 50.00 Sodium Starch Glycolate 20.00 20.00 Colloidal Silicon Dioxide 1.60 1.60 Talc 4.00 4.00 Magnesium Stearate 6.00 6.00 Final Mixing Sodium Starch Glycolate 20.00 20.00 Colloidal Silicon Dioxide 2.40 2.40 Magnesium Stearate 4.00 4.00 Total Amount 390 390 Dapagliflozin Compacting Dapagliflozin Propanediol 12.30 12.30 Microcrystalline cellulose 99.10 - Lactose monohydrate - 99.10 Anhydrous calcium phosphate - D-mannitol 90.00 90.00 Hydroxypropyl cellulose 10.00 10.00 Sodium stearyl fumarate 12.00 12.00 Final mixture Croscarmellose sodium 20.00 20.00 Sodium stearyl fumarate 8.00 8.00 Total 251.4 251.4

[0350]

[0351] [Example 7] Preparation of drug-coated tablets containing sacubitril-valsartan and dapagliflozin

[0352] The final mixture of sacubitril and valsartan was prepared in the same manner as in Example 5, and then compressed into tablets using a tablet press to produce uncoated tablets. To prepare a drug coating solution, a coating solution containing dapagliflozin, povidone, and macrogol-polyvinyl alcohol copolymer was prepared in 200 mg of purified water and 200 mg of ethanol per 1T with the composition shown in Table 17 below. Afterwards, a high-speed coalescer (XENA-IV, Raon) was used at a supply air temperature of 55°C, a non-superheater temperature of 45°C, a fan speed of 6 rpm, and an air pressure gauge of 2 to 4 kgf / cm. 2 The coating solution was coated on the surface of the substrate under the conditions.

[0353] Process Prescription Amount (mg / tablet) Example 7 Sacubitril-Valsartan Compacting Sacubitril-Valsartan Trisodium 2.5 Hydrate 226.2 Microcrystalline Cellulose 55.8 Low-Substituted Hydroxypropyl Cellulose 50.00 Sodium Starch Glycolate 20.00 Colloidal Silicon Dioxide 1.60 Talc 4.00 Magnesium Stearate 6.00 Final Mixing Sodium Starch Glycolate 20.00 Colloidal Silicon Dioxide 2.40 Magnesium Stearate 4.00 Total Amount 390 Dapagliflozin Drug Coating Dapagliflozin Propanediol 12.30 Povidone 2.80 Macrogol-Polyvinyl Alcohol Copolymer 20.00 Total Amount 35.1

[0354]

[0355] [Example 8] Preparation of a bilayer tablet containing sacubitril-valsartan and dapagliflozin

[0356] Sacubitril-valsartan, microcrystalline cellulose, D-mannitol, low-substituted hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, talc, and magnesium stearate were mixed according to the composition shown in Table 18 below and placed in a roller compactor to prepare dry granules. Croscarmellose sodium and colloidal silicon dioxide were mixed to prepare a second mixed powder, and then magnesium stearate was post-mixed to prepare a sacubitril-valsartan final mixed powder (first mixed powder). Then, dapagliflozin propanediol, microcrystalline cellulose, D-mannitol, hydroxypropyl cellulose, croscarmellose sodium, and sodium stearyl fumarate were mixed and placed in a roller compactor to prepare dry granules. Afterwards, croscarmellose sodium was mixed into the granules to produce a secondary mixed powder, and then sodium stearyl fumarate was post-mixed to produce the final mixed powder of dapagliflozin (second mixed powder). The final mixed powder of sacubitril-valsartan was placed as the lower layer, and the final mixed powder of dapagliflozin was placed as the upper layer. The tablets were compressed into two-layer tablets (hardness of approximately 15 KP) using an oval punch measuring 17.5 mm in width and 9 mm in length using a tableting machine (Autotab-200TR, Ichihashi Seiki) at a compression pressure of 10 KN.

[0357] Process Prescription Amount (mg / tablet) Example 8 Sacubitril-Valsartan (Lower layer) Dry granules Sacubitril-Valsartan trisodium 2.5 hydrate 226.2 Microcrystalline cellulose 27.1 D-mannitol 19.7 Low-substituted hydroxypropyl cellulose 59.0 Croscarmellose sodium 20.0 Colloidal silicon dioxide 1.5 Talc 4.0 Magnesium stearate 6.0 2nd Mixed croscarmellose sodium 20.0 Colloidal silicon dioxide 2.5 Final mixed magnesium stearate 4.0 Total 390 Dapagliflozin (Upper layer) Compacting dapagliflozin propanediol 12.3 Microcrystalline cellulose 39.4 D-mannitol 113.6 Hydroxypropyl cellulose 10.0 Sodium stearyl fumarate 8.4 2nd Mixed croscarmellose sodium 20.0, final mixed sodium stearyl fumarate 6.3, total 210

[0358] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred implementation examples and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0359] The present invention relates to a pharmaceutical combination formulation comprising sacubitril-valsartan and an SGLT-2 inhibitor, which can be used to treat heart failure, ischemic heart disease, and the like. The pharmaceutical combination formulation provided by the present invention exhibits excellent stability and dissolution rate.

Claims

1. (1) a first release portion comprising sacubitril-valsartan or a pharmaceutically acceptable salt thereof as an active ingredient; and (2) A pharmaceutical combination preparation comprising a second release portion comprising an SGLT-2 (Sodium-Glucose Cotransporter 2) inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient.

2. In paragraph 1, A pharmaceutical combination preparation wherein the first release portion and the second release portion are physically separated from each other.

3. In paragraph 1, The above pharmaceutical combination preparation is a multilayer tablet or a drug-coated tablet.

4. In paragraph 1, A pharmaceutical combination preparation wherein the SGLT-2 inhibitor is selected from the group consisting of dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, sotagliflozin, ipragliflozin, tofogliflozin, luseogliflozin, bexagliflozin, and remogloflozin.

5. In paragraph 1, A pharmaceutical combination preparation, wherein the first or second release portion comprises at least one pharmaceutically acceptable additive selected from the group consisting of excipients, disintegrants, and lubricants.

6. In paragraph 5, A pharmaceutical combination preparation wherein the excipient is selected from the group consisting of microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminometasilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose hydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate hydrate, calcium carbonate, sugars, and mixtures thereof.

7. In paragraph 5, A pharmaceutical combination preparation wherein the disintegrant is selected from the group consisting of crospovidone, methylcellulose, cross-linked carboxymethylcellulose sodium (Cross-linked CMC Na, C.CMC Na, or croscarmellose sodium), carboxymethylcellulose calcium, sodium starch glycolate, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, alginic acid or its sodium salt, and combinations thereof.

8. In paragraph 5, A pharmaceutical combination preparation wherein the above-mentioned lubricant is selected from the group consisting of calcium stearate, colloidal fumed silica, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid, hydrogenated vegetable oil, polyethylene glycol, sodium benzoate, talc, and combinations thereof.

9. In paragraph 1, A pharmaceutical combination formulation, wherein the second release unit comprises a coating agent.

10. In paragraph 9, A pharmaceutical combination preparation wherein the coating agent is at least one selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), polyvinyl alcohol (PVA), macrogol polyvinyl alcohol graft copolymer, polymers of acrylic acid and salts thereof, polymethacrylate, poly(butyl methacrylate, 2-dimethylaminoethyl methacrylate, methyl methacrylate) copolymer, carboxymethylcellulose, ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethyl cellulose, hydroxypropylcellulose (HPC), L-HPC (low-substituted HPC), polyvinylpyrrolidone (PVP), vinylpyrrolidone-vinylacetate copolymer, gelatin, guar gum, partially hydrolyzed starch, alginate, xanthan and mixtures thereof.

11. In paragraph 1, A pharmaceutical combination formulation, wherein the first release portion comprises, based on the total weight, 10 to 80 wt% of an active ingredient, 1 to 50 wt% of an excipient, 5 to 50 wt% of a disintegrant, and 0.1 to 20 wt% of a lubricant.

12. In paragraph 1, A pharmaceutical combination preparation, wherein the second release portion comprises, based on the total weight, 0.5 to 50 wt% of an active ingredient, 20 to 95 wt% of an excipient, 0.1 to 20 wt% of a disintegrant, and 0.1 to 20 wt% of a lubricant.

13. In paragraph 1, A pharmaceutical combination formulation, wherein the second release portion comprises 10 to 70 wt% of an effective ingredient and 30 to 90 wt% of a coating agent based on the total weight.

14. In paragraph 1, A pharmaceutical combination preparation, wherein the first release portion comprises, based on the total weight of the first release portion, 10 to 80 wt% of an active ingredient, 5 to 50 wt% of at least one of microcrystalline cellulose and mannitol, 5 to 30 wt% of low-substituted hydroxypropyl cellulose, 5 to 30 wt% of at least one of sodium starch glycolate and sodium croscarmellose, 0.1 to 10 wt% of colloidal silicon dioxide, 0.1 to 10 wt% of talc, and 0.1 to 10 wt% of magnesium stearate.

15. In paragraph 1, A pharmaceutical combination preparation, wherein the second release portion comprises, based on the total weight of the second release portion, 0.5 to 50 wt% of an active ingredient, 10 to 50 wt% of at least one of microcrystalline cellulose and lactose hydrate, 10 to 50 wt% of mannitol, 0.1 to 20 wt% of hydroxypropyl cellulose, 0.5 to 20 wt% of croscarmellose sodium, and 0.5 to 20 wt% of stearyl fumarate sodium.

16. In paragraph 1, The pharmaceutical combination formulation comprises a first layer comprising a first release portion comprising sacubitril-valsartan or a pharmaceutically acceptable salt thereof as an active ingredient; and A pharmaceutical combination preparation comprising a second layer comprising a second release portion comprising the SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient.

17. In paragraph 1, The pharmaceutical combination formulation comprises a core comprising a first release portion comprising the sacubitril-valsartan or a pharmaceutically acceptable salt thereof as an active ingredient; and A pharmaceutical combination formulation comprising a drug-coated tablet comprising a coating layer comprising a second release portion comprising the SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, the second release portion being positioned on at least a portion of the core surface.

18. In paragraph 1, The first release portion comprises granules containing the active ingredient of sacubitril-valsartan or a pharmaceutically acceptable salt thereof, an excipient, a disintegrant and a lubricant, and a post-mixing portion containing the disintegrant and the lubricant, A pharmaceutical combination formulation, wherein the second release portion comprises granules containing the active ingredient of the SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof, an excipient, a disintegrant and a lubricant, and a post-mixing portion containing the disintegrant and the lubricant. 19.(a) A step of preparing a first release portion comprising sacubitril-valsartan or a pharmaceutically acceptable salt thereof as an active ingredient; (b) a step of preparing a second release portion comprising an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient; and (c) A method for producing a pharmaceutical combination preparation, comprising the step of formulating the first release portion and the second release portion into one solid preparation.

20. In paragraph 19, A method for producing a pharmaceutical combination preparation, comprising the steps of (a) preparing the first release portion, (a-1) mixing sacubitril-valsartan or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable additive; (a-2) preparing granules; and (a-3) mixing the granules with the post-mixing portion.

21. In paragraph 20, A method for manufacturing a pharmaceutical combination preparation, further comprising a step of (a-4) tableting after the step (a-3).

22. In paragraph 20, A method for producing a pharmaceutical combination preparation, wherein the step of producing the second release portion (b) comprises: (b-1) mixing an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable additive; (b-2) preparing granules; and (b-3) mixing the granules with a post-mixing portion.

23. In paragraph 22, A method for producing a pharmaceutical combination preparation, wherein the step of formulating into a solid preparation (c) includes a step of producing a bilayer tablet by compressing the mixed powder of the first release portion obtained in the step (a-3) and the mixed powder of the second release portion obtained in the step (b-3).

24. In paragraph 21, The step of preparing the second release portion (b) above includes the step of preparing a coating solution by mixing (b-1) an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof and a coating agent, A method for producing a pharmaceutical combination formulation, wherein the step of formulating into a solid formulation (c) comprises a step of coating the core in the tablet form obtained in the step (a-4) with a coating solution of the second release portion obtained in the step (b-1).